WO2010007482A2 - Thiazole derivatives as stearoyl coa desaturase inhibitors - Google Patents

Thiazole derivatives as stearoyl coa desaturase inhibitors Download PDF

Info

Publication number
WO2010007482A2
WO2010007482A2 PCT/IB2009/006146 IB2009006146W WO2010007482A2 WO 2010007482 A2 WO2010007482 A2 WO 2010007482A2 IB 2009006146 W IB2009006146 W IB 2009006146W WO 2010007482 A2 WO2010007482 A2 WO 2010007482A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
unsubstituted
thiazole
ethynyl
carboxamide
Prior art date
Application number
PCT/IB2009/006146
Other languages
French (fr)
Other versions
WO2010007482A3 (en
Inventor
Laxmikant Atmaram Gharat
Lakshminarayana Narayana
Abraham Thomas
Neelima Khairatkar-Joshi
Daisy Manish Shah
Original Assignee
Glenmark Pharmaceuticals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals S.A. filed Critical Glenmark Pharmaceuticals S.A.
Publication of WO2010007482A2 publication Critical patent/WO2010007482A2/en
Publication of WO2010007482A3 publication Critical patent/WO2010007482A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present patent application relates to Thiazole derivatives with SCDl activity.
  • Metabolic energy balance is important for well-being which is maintained by appropriate adjustment between energy intake and energy expenditure.
  • Primary defects in energy balance produce obesity. Over the past few years there has been a sharp increase in obesity in many countries. Obesity is a principal cause of morbidity and mortality mainly because it increases risk for other conditions that shorten life, including diabetes, insulin resistance, coronary artery disease, hypertension and non-alcoholic fatty liver disease collectively known as metabolic syndrome (J Am. Med. Assoc, (2002), 288, 1723-1727). Obesity has been identified as an independent risk factor for the development of type 2 diabetes.
  • liver fatty acids accumulate causing an increase in hepatic lipid content or get packaged into the very low density lipoprotein for export to other peripheral tissues.
  • Liver steatosis associated with obesity can also result from an enhanced rate of de novo fatty acid synthesis and/or dysregulation of intracellular lipid partitioning in which fatty acid oxidation is impaired and its esterification enhanced.
  • Lipid abnormalities in obese subjects are atherogenic.
  • the dyslipidemic state initiates a cascade of events including release of proinflammatory adipokines which induces a proinflammatory state that drives pathogenesis of atherosclerosis.
  • Increased release of proinflammatory adipokines also increases fibrinogen and plasminogen activator inhibitor levels thereby increasing risk for arterial thrombosis.
  • proinflammatory adipokines also increases fibrinogen and plasminogen activator inhibitor levels thereby increasing risk for arterial thrombosis.
  • Several studies show that even modest weight gain can precipitate the onset of hypertension (Ann. Rev. Med, (2005), 56, 45-62). Hence obesity alone can drive all aspects of the metabolic syndrome. It is believed that effective treatment of obesity could lead to prevention and control of metabolic syndrome (Obesity Reviews, (2005), 6, 169-174).
  • SCDl Stearoyl CoA desaturase 1
  • SCDl has two preferred substrates palmitoyl and stearoyl CoA, which are desaturated to palmitoleoyl and oleoyl CoA respectively (J Biol Chem., 25_i, 5095-5103 (1976)).
  • Oleate is found to be the major monounsaturated fatty acid of membrane phospholipids, triglycerides, cholesterol esters, wax esters and alkyl-1, 2-diacylglycerol.
  • the ratio of stearate to oleate is one of the factors influencing membrane fluidity and its alteration is important in diseases like aging, cancer, diabetes, obesity, and neurological, vascular and heart diseases (Biochem. Biophys.
  • mice with targeted disruption in the SCDl gene are resistant to diet-induced obesity and have reduced body adiposity, liver lipid accumulation and postprandial plasma insulin and glucose levels, with concomitant increase in the metabolic rate, thermogenesis and insulin sensitivity (J Nutr., (2001), 131, 2260-2268; PNAS, (2002), 99, 11482-11486).
  • SCDl is documented as a key enzyme in regulating hepatic lipogenesis and lipid oxidation and therapeutic manipulation of SCD can be of benefit in treatment of obesity and metabolic syndrome (Obesi. Reviews, J) 1 169-174 (2005); Curr. Drug Targets Immune Endocr Metabol Disord., (2003), 3, 271-280).
  • CLA Conjugated linoleic acid
  • Sterculic acid (8-(2-octylcyclopropenyl) octanoic acid) and malvalic acid (7- (2-octylcyclopropenyl)heptanoic acid) are Cl 8 and Cl 6 derivatives of sterculoyl and malvaloyl fatty acids, respectively and inhibit SCD enzymatic activity by direct interaction with the enzyme.
  • SCDl antisense oligonucleotide inhibitors specifically reduce SCDl expression thereby reducing fatty acid synthesis and secretion, body adiposity, hepatomegaly, steatosis and prevent obesity in mice by improving energy balance (J Clinical Investigation., (2005) F 1- 9).
  • US 2006/009459 and WO 2005/011653, WO 2005/01164, WO 2005/011655, WO 2005/011656 and WO 2005/011657 disclose certain pyridazine derivatives, pyridyl derivatives, and piperazine derivatives and their use for inhibiting human stearoyl-CoA desaturase (hSCD) activity.
  • US 2004/072877 is directed to a method for increasing insulin sensitivity by reducing stearoyl CoA desaturase 1 (SCDl) activity in a subject sufficiently to increase insulin sensitivity.
  • SCDl stearoyl CoA desaturase 1
  • the present invention provides Thiazole compounds as SCDl inhibitors, which are used in the treatment of diseases, conditions or disorders modulated by SCDl, and processes for the synthesis of these compounds.
  • the compound of the present invention is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl
  • R is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted cycloalkyl
  • R 1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkyl, fully or partially substituted haloalkyl, substituted or unsubstituted haloalkyloxy, fully or partially substituted haloalkyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, or substituted or unsubstituted heteroaryl;
  • R 2 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl; wherein substituents are independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkyl, fully or partially substituted haloalkyl, substituted or unsubstituted haloalkyloxy, fully or partially substituted haloalkyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, or substituted or unsubstituted heteroaryl; at each occurrence R 3 is independently selected from hydrogen, hydroxyl, cyano
  • R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl;
  • 'n' is an integer selected from 1 to 5, both inclusive;
  • L is (C 1 -C 6 ) alkylene linker which may be further substituted with halogen or alkyl.
  • R 1 is substituted or unsubstituted cycloalkyl (eg., cyclopropyl), fully or partially substituted haloalkyl (eg., trifluoroalkyl).
  • R 2 is substituted or unsubstituted aryl; wherein aryl is preferably unsubstituted phenyl.
  • R 2 is substituted or unsubstituted aryl; wherein aryl is preferably mono substituted phenyl.
  • substituent is halogen (eg., fluorine, chlorine), alkoxy (eg., methoxy) or haloalkyl (eg., trifluoroalkyl).
  • R 2 is substituted or unsubstituted aryl; wherein aryl is preferably di or tri substituted phenyl.
  • substituents are independently selected from halogen (eg., fluorine, chlorine or bromine).
  • R 2 is substituted or unsubstituted heteroaryl, preferably pyridine.
  • R 3 is independently selected from fluoro, hydroxy, methyl, ethyl, trifluoromethyl, or triflouoromethoxy; preferably hydroxy.
  • 'n' is 1 or 2.
  • composition comprising a therapeutically effective amount of one or more compounds of Formula (I) and optionally one or more pharmaceutically acceptable excipients, carriers, diluents or mixture thereof.
  • provided herein is a method for preventing, ameliorating or treating a disease, disorder or syndrome modulated by SCDl in a subject comprising administering to the subject in need thereof a therapeutically effective amount of one or more compounds of Formula (I), or a pharmaceutical composition as described herein.
  • a method of inhibiting lipid metabolism that proceeds via a Stearoyl-CoA Desaturase-1 (SCDl) mediated pathway in a subject, the method including administering to the subject in need thereof a therapeutically effective amount of one or more compounds of Formula I, that exhibits increased SCDl inhibitory activity in a target tissue in comparison with SCDl activity in a reference tissue.
  • SCDl Stearoyl-CoA Desaturase-1
  • the target and reference tissues are selected from liver and skin.
  • the target tissue is liver and the reference tissue is skin.
  • the selective SCDl inhibitor is believed to decrease conversion of saturated fatty acids to unsaturated fatty acids in liver cells to a greater extent than in skin cells.
  • the preferred fatty acids are selected from palmitoyl CoA and stearoyl CoA.
  • the subject is a cell.
  • the subject is a mammal, preferably, a human.
  • the preferred ratio of EC35 for the SCD-I inhibitor in skin cells to that in liver cells is greater than 1.
  • halogen or halo includes fluorine, chlorine, bromine, or iodine.
  • alkyl refers to hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1- methylethyl (isopropyl), n-butyl, «-pentyl, and 1,1-dimethylethyl (tert-bnty ⁇ ).
  • Cj -6 alkyl refers to an alkyl chain having 1 to 6 carbon atoms. Unless set forth or recited to the contrary, all alkyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • alkenyl refers to an hydrocarbon chain containing from 2 to 10 carbon atoms and including at least one carbon-carbon double bond.
  • alkenyl groups include ethenyl, 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-l- propenyl, 1-butenyl, and 2-butenyl. Unless set forth or recited to the contrary, all alkenyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • alkynyl refers to a hydrocarbyl radical having at least one carbon-carbon triple bond, and having 2 to about 12 carbon atoms (with radicals having 2 to about 10 carbon atoms being preferred).
  • Non-limiting examples of alkynyl groups include ethynyl, propynyl, and butynyl. Unless set forth or recited to the contrary, all alkynyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • alkylene refers to divalent of alkyl group, wherein alkyl is as defined above.
  • haloalkyl is used to denote a group comprised of an alkyl group substituted with halogen atom, where alkyl group is as defined above and halogen is used to denote fluorine, chlorine, bromine or iodine, an example of such group is trifluoromethyl, difluoromethyl.
  • alkoxy denotes an alkyl group attached via an oxygen linkage to the rest of the molecule. Representative examples of such groups are -OCH 3 and -OC 2 H 5 . Unless set forth or recited to the contrary, all alkoxy groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
  • haloalkoxy refers to an haloalkyl group attached via an oxygen linkage to the rest of the molecule.
  • Representative examples of such groups are -OCF 3 and -OC 2 Fs.
  • cycloalkyl denotes a non-aromatic mono or multicyclic ring system of 3 to about 12 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • multicyclic cycloalkyl groups include, but are not limited to, perhydronapththyl, adamantyl and norbornyl groups, bridged cyclic groups or sprirobicyclic groups, e.g., sprio(4,4)non-2-yl. Unless set forth or recited to the contrary, all cycloalkyl groups described or claimed herein may be substituted or unsubstituted.
  • cycloalkylalkyl refers to a cyclic ring-containing radical having 3 to about 8 carbon atoms directly attached to an alkyl group.
  • the cycloalkylalkyl group may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure.
  • Non-limiting examples of such groups include cyclopropylmethyl, cyclobutylethyl, and cyclopentylethyl. Unless set forth or recited to the contrary, all cycloalkylalkyl groups described or claimed herein may be substituted or unsubstituted.
  • cycloalkenyl refers to a cyclic ring-containing radical having 3 to about 8 carbon atoms with at least one carbon-carbon double bond, such as cyclopropenyl, cyclobutenyl, and cyclopentenyl. Unless set forth or recited to the contrary, all cycloalkenyl groups described or claimed herein may be substituted or unsubstituted.
  • aryl refers to an aromatic radical having 6 to 14 carbon atoms, including monocyclic, bicyclic and tricyclic aromatic systems, such as phenyl, naphthyl, tetrahydronapthyl, indanyl, and biphenyl. Unless set forth or recited to the contrary, all aryl groups described or claimed herein may be substituted or unsubstituted.
  • arylalkyl refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g., -CH 2 C 6 H 5 and -C 2 H 5 C 6 H 5 .
  • heterocyclyl and "heterocyclic ring” "heterocyclic group” refers to a stable 3- to 15-membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from nitrogen, phosphorus, oxygen and sulfur.
  • the heterocyclic ring radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states.
  • the nitrogen atom may be optionally quaternized; and the ring radical may be partially or fully saturated (i.e., heterocyclic or heteroaryl).
  • heterocyclic ring radicals include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazolyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pyridyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazolyl, imidazolyl, tetrahydroisoquinolinyl,
  • heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
  • heterocyclyl groups described or claimed herein may be substituted or unsubstituted, including those included in more complex substructures.
  • heteroaryl refers to an aromatic heterocyclic ring radical.
  • the heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure.
  • all heteroaryl groups described or claimed herein may be substituted or unsubstituted, including those included in more complex substructures.
  • heterocyclylalkyl refers to a heterocyclic ring radical directly bonded to an alkyl group.
  • the heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure.
  • heteroarylalkyl refers to a heteroaryl ring radical directly bonded to an alkyl group.
  • the heteroarylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure.
  • prodrug refers to a compound that is transformed in vivo to yield a compound of formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms, such as through hydrolysis in blood.
  • a discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems, 1 " Vol. !_4 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed Edward B. Roche, American Pharmaceutical Association and Pergamon Press, (1987).
  • inhibiting lipid metabolism that proceeds via an SCD-I -mediated pathway denotes alteration in normal functioning of lipid metabolic pathway that involves SCD-I enzyme, including, particularly, a decrease in lipid formation via a pathway facilitated by the SCD-I enzyme.
  • selective SCD-I inhibitor denotes a substance that affects activity of SCD-I enzyme in a differential manner, particularly, a substance that selectively affects SCD activity in one tissue type as compared to SCD-I activity of the same substance in another tissue type.
  • a substance is a selective SCD-I inhibitor if the SCD-I inhibitory activity of the substance in target tissue is greater than SCD-I inhibitory activity of the substance in reference tissue.
  • An agent may be a selective inhibitor for liver SCD-I by having a lower EC 35 in liver cells than in skin cells.
  • target tissue with respect to SCD-I activity denotes a tissue type in which SCD-I inhibition is intended to be exerted via administration of a substance having SCD-I inhibitory activity.
  • target tissue include liver, skin and cornea.
  • reference tissue with respect to SCD-I activity denotes a tissue type in which SCD-I inhibition is not intended to be exerted via administration of a substance having SCD-I inhibitory activity.
  • Non-limiting example of a “reference tissue” include liver, skin and cornea.
  • EC 35 refers to the concentration of the compound which inhibits the activity of the enzyme halfway between the baseline and maximum response of approximately 70%.
  • IC 50 refers to the concentration of inhibitor that reduces enzyme activity by 50%.
  • treating or “treatment” of a state, disorder or condition includes: (a) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a subject that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (b) inhibiting the state, disorder or condition, i.e., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof; or (c) relieving the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
  • subject includes mammals (especially humans) and other animals, such as domestic animals (e.g., household pets including cats and dogs) and non-domestic animals (such as wildlife).
  • domestic animals e.g., household pets including cats and dogs
  • non-domestic animals such as wildlife.
  • a “therapeutically effective amount” means the amount of a compound that, when administered to a subject for treating a state, disorder or condition, is sufficient to cause the effect in the subject which is the purpose of the administration.
  • the “therapeutically effective amount” will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the subject to be treated.
  • Pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic bases (such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, and Mn), salts of organic bases (such as N,N'-diacetylethylenediamine, glucamme, triethylamine, choline, hydroxide, dicyclohexylamine, metformin, benzylamine, trialkylamine, and thiamine), salts of chiral bases (such as alkylphenylamine, glycinol, and phenyl glycinol), salts of natural amino acids (such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, and serine), salts of non-natural amino acids (such as D-
  • salts include acid addition salts (where appropriate) such as sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates (such as trifluoroacetate), tartrates, maleates, citrates, fumarates, succinates, palmoates, methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates, and ketoglutarates.
  • acid addition salts such as sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates (such as trifluoroacetate), tartrates, maleates, citrates, fumarates, succinates, palmoates, methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates, and ketoglutarates.
  • Compounds described herein can comprise one or more asymmetric carbon atoms and thus can occur as racemic mixtures, enantiomers and diastereomers. These compounds can also exist as conformers/rotamers. All such isomeric forms and/or regiomers of these compounds are expressly included in the present invention, although the specific compounds exemplified in this application may be depicted in a particular stereochemical configuration, compounds having either the opposite stereochemistry at any given chiral centre are envisioned as a part thereof.
  • the pharmaceutical composition of the present invention comprises one or more compounds described herein and one or more pharmaceutically acceptable excipients, carriers, diluents or mixture thereof.
  • the compounds described herein may be associated with one or more pharmaceutically acceptable excipients, carriers, diluents or mixture thereof in the form of capsule, sachet, paper or other container.
  • suitable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextriri, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethyl cellulose and polyvinylpyrrolidone.
  • the carrier or diluent may include a sustained release material, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
  • the pharmaceutical composition may also include one or more pharmaceutically acceptable auxiliary agents, wetting agents, emulsifying agents, suspending agents, preserving agents, salts for influencing oxmetic pressure, buffers, sweetening agents, flavouring agents, colorants, or any combination of the foregoing.
  • the pharmaceutical composition of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the subject by employing methods known in the art.
  • compositions of the present invention may be prepared by conventional techniques, e.g., as described in Remington: The Science and Practice of Pharmacy, 20 th Ed., 2003 (Lippincott Williams & Wilkins).
  • the active compound is mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of an ampoule, capsule, sachet, paper, or other container.
  • the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material that acts as a vehicle, excipient, or medium for the active compound.
  • the active compound is adsorbed on a granular solid container, for example, in a sachet.
  • compositions may be in conventional forms, for example, capsules, tablets, aerosols, solutions, suspensions or products for topical application.
  • the route of administration may be any route which effectively transports the active compound of the invention to the appropriate or desired site of action.
  • Suitable routes of administration include, but are not limited to, oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal, parenteral, rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic (such as with an ophthalmic solution) or topical (such as with a topical ointment).
  • the oral route is preferred.
  • Solid oral formulations include, but are not limited to, tablets, capsules (soft or hard gelatin), dragees (containing the active ingredient in powder or pellet form), troches and lozenges. Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, cornstarch, and/or potato starch. A syrup or elixir is used in cases where a sweetened vehicle is employed.
  • Liquid formulations include, but are not limited to, syrups, emulsions, soft gelatin and sterile injectable liquids, such as aqueous or non-aqueous liquid suspensions or solutions.
  • injectable solutions or suspensions preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
  • Suitable doses of the compounds for use in treating the diseases and disorders described herein can be determined by those skilled in the relevant art.
  • Therapeutic doses are generally identified through a dose ranging study in humans based on preliminary evidence derived from the animal studies. Doses must be sufficient to result in a desired therapeutic benefit without causing unwanted side effects.
  • Mode of administration, dosage forms, suitable pharmaceutical excipients, diluents or carriers can also be well used and adjusted by those skilled in the art. AU changes and modifications are envisioned within the scope of the present invention.
  • the present invention further provides a method of treating a disease, condition or disorder modulated by a stearoyl CoA desaturase, especially those modulated by SCDl, in a subject by administering to the subject in need thereof a therapeutically effective amount of a compound or a pharmaceutical composition described herein.
  • Diseases, conditions, and disorders that are modulated by a stearoyl CoA desaturase include, but are not limited to, diabetes, diabetes related syndromes, disorders or diseases obesity, obesity related diseases, conditions, and disorders, cardiovascular diseases (such as atherosclerosis), hepatic steatosis and other metabolic syndromes, metabolism related syndromes, disorders and diseases, and non-alcoholic fatty liver disease.
  • SCD can be regulated to treat obesity.
  • Obesity and overweight are defined as an excess of body fat relative to lean body mass.
  • An increase in caloric intake or a decrease in energy expenditure or both can bring about this imbalance leading to surplus energy being stored as fat.
  • anorexia and cachexia are characterized by an imbalance in energy intake versus energy expenditure leading to a negative energy balance and weight loss.
  • Agents that either increase energy expenditure and/or decrease energy intake, absorption or storage would be useful for treating obesity, overweight, and associated comorbidities.
  • Agents that increase energy intake and/or decrease energy expenditure or increase the amount of lean tissue would be useful for treating cachexia, anorexia, and wasting disorders.
  • An SCD gene, translated proteins and agents which modulate the gene or portions of the gene or its products are useful for treating obesity, overweight, anorexia, cachexia, wasting disorders, appetite suppression, appetite enhancement, increases or decreases in satiety, modulation of body weight, and/or other eating disorders such as bulimia.
  • diseases, conditions, and disorders that are modulated by a stearoyl CoA desaturase include, but are not limited to, obesity, overweight, anorexia, cachexia, wasting disorders, appetite suppression, appetite enhancement, and other eating disorders such as bulimia.
  • the compounds of the present invention increase or decrease in satiety and modulate body weight.
  • Obesity related syndromes, disorders and diseases include, but are not limited to, obesity as a result of (i) genetics, (ii) diet, (iii) food intake volume, (iv) a metabolic disorder, (v) a hypothalmic disorder, (vi) age, (vii) abnormal adipose mass distribution, (viii) abnormal adipose compartment distribution, (ix) compulsive eating disorders, and (x) motivational disorders which include the desire to consume sugars, carbohydrates, alcohols or drugs or any ingredient with hedonic value.
  • Symptoms associated with obesity related syndromes, disorders, and diseases include, but are not limited to, reduced activity. Obesity also increases the likelihood of sleep apnea, gallstones, osteoporosis and ceratin cancers.
  • Diabetes related syndromes, disorders and diseases include, but are not limited to, glucose dysregulation, insulin resistance, glucose intolerance, hyperinsulinemia, dyslipidemia, hypertension, obesity, and hyperglycemia.
  • Cardiovascular diseases include, but are not limited to, (i) coronary artery disease, (ii) atherosclerosis, (iii) heart disease, (iv) hypercholesterolemia, (v) hypertriglyceridemia, (vi) hypertriglyceridemia secondary to another disorder or disease (such as hyperlipoproteinemias), (vii) hyperlipidemia, (viii) disorders of serum levels of triglycerides, VLDL, HDL, and LDL, (ix) cholesterol disorders, (x) cerebrovascular disease (including but not limited to, stroke, ischemic stroke and transient ischemic attack (TIA)), (xi) peripheral vascular disease, and (xii) ischemic retinopathy.
  • TIA ischemic stroke and transient ischemic attack
  • Metabolism related syndromes, disorders or diseases include, but are not limited to, (i) metabolic syndrome, (ii) dyslipidemia, (iii) elevated blood pressure, (iv) insulin sensitivity or resistance, (v) type II diabetes, (vi) type I diabetes, (vii) diabetic complications, (viii) increased abdominal girth, (ix) glucose tolerance, (x) microalbuminemia, (xi) hyperuricaemia, (xii) hyperinsulinemia, (xiii) hypercholesterolemia, (xiv) hyperlipidemias, (xv) atherosclerosis, (xvi) hypertriglyceridemias, (xvii) arteriosclerosis and other cardiovascular diseases, (xviii) osteoarthritis, (xix) dermatological diseases, (xx) sleep disorders (e.g., disturbances of circadian rhythm, dysomnia, insomnia, sleep apnea and narcolepsy), (xxi) cholelithiasis, (xxii) hepatomegaly,
  • compounds of the invention will, in a subject, increase HDL levels and/or decrease triglyceride levels and/or decrease LDL or non-HDL-cholesterol levels.
  • compounds of the invention will, in a subject, increase body lean mass and decrease obesity.
  • compounds of the invention will, in a subject, decrease hepatic steatosis.
  • the diseases, disorders, and syndromes are selected, but are not limited to, obesity, for example, obesity resulting from genetics, diet, food intake volume, a metabolic disorder, a hypothalmic disorder, age, abnormal adipose mass distribution, abnormal adipose compartment distribution, compulsive eating disorders, motivational disorders, which include the desire to consume sugars, carbohydrates, alcohols or drugs or any ingredient with hedonic value, reduced activity or combination thereof; overweight conditions; anorexia; bulimia; cachexia; dysregulated appetite; or obesity related diseases, disorders, and symptoms; diabetes (including Type I and Type II diabetes); diabetic complications; glucose tolerance; hyperinsulinemia; insulin sensitivity or resistance; hepatic steatosis; increased abdominal girth; metabolic syndrome; cardiovascular diseases including, for example, atherosclerosis, dyslipidemia, elevated blood pressure, microalbuminemia, hyperuricaemia, hypercholesterolemia, hyperlipidemias, at
  • diabetes including Type I and Type II diabetes
  • diabetic complications glucose tolerance
  • hyperinsulinemia insulin sensitivity or resistance
  • metabolic syndromes cardiovascular diseases including, for example, atherosclerosis, lipidemia, dyslipidemia, elevated blood pressure, microalbuminemia, hyperuricaemia,
  • a method for preventing, ameliorating or treating a disease or condition related to serum levels of triglyceride, LDL, HDL, VLDL, total cholesterol there is provided a method for preventing, ameliorating or treating a disease or condition selected from obesity or complication thereof, type II diabetes or complication thereof; cardiovascular diseases or complication thereof, or a combination of these.
  • Scheme 1 depicts a method for preparing the compounds described by general formula (I) wherein all symbols are as defined above.
  • compound of formula (A) is converted to a compound of formula (B) wherein X is halogen, for example, by reacting with molecular halogen or with a halo substituted succinimide in a halogenated solvent or acetonitrile, THF, diethyl ether, acetic acid or the like known in the art of organic synthesis.
  • Compound of formula (B) is converted to a compound of formula (C) by reacting with thiourea (J Chem. Soc, Perkin Trans 1, (1982), 159-164) known in the art of organic synthesis.
  • Compound of formula (C) is converted to a compound of formula (D) by reacting under Sandmeyer reaction conditions with an alkali nitrite in an aqueous acid in the presence of an alkali halide known in the art of organic synthesis.
  • Compound of formula (D) is converted to a compound of formula (E) by reacting with an aqueous alkali under standard ester hydrolysis conditions known in the art of organic synthesis.
  • Compound of formula (E) is converted to a compound of formula (F) by reacting with an appropriately substituted amine under standard amidation conditions employing a coupling reagent such as EDCI.HC1 (l-ethyl-3-(3-dimethylaminopropyl) carbodiimide) hydrochloride) or BOP (benzotriazol-1- yloxytris(dimethylamino)-phosphonium hexafluorophosphate) in the presence of a base such as triethylamine or diisopropylethylamine with or without a catalyst such as DMAP (Dimethylaminopyridine) as known in the art of organic synthesis.
  • a coupling reagent such as EDCI.HC1 (l-ethyl-3-(3-dimethylaminopropyl) carbodiimide) hydrochloride) or BOP (benzotriazol-1- yloxytris(dimethylamino)-
  • Compound of formula (F) is converted to a compound of formula (I) by reacting with an appropriately substituted acetylene under Sonogashira reaction conditions using a base such as triethylamine, diisopropylethylamine or the like or tetra- ⁇ -butylammonium fluoride with or without a solvent like DMSO (Dimethyl sulfoxide) in the presence of a copper catalyst such as copper iodide and a palladium catalyst such as (tetrakistriphenylphosphine)palladium(O), in the temperature range of room temperature to 100 0 C.
  • a base such as triethylamine, diisopropylethylamine or the like or tetra- ⁇ -butylammonium fluoride with or without a solvent like DMSO (Dimethyl sulfoxide)
  • a copper catalyst such as copper iodide
  • a palladium catalyst such as (tetraki
  • Compound of formula (G) is converted to a compound of formula (Ff) by reacting with a silyl acetylene under Sonogashira reaction conditions using a base such as triethylamine, diisopropylethylamine etc., in a solvent such as DMSO in the presence of copper iodide and a palladium catalyst such as (tetrakistriphenylphosphine)palladium(O), in the temperature range of room temperature to 100 0 C.
  • a base such as triethylamine, diisopropylethylamine etc.
  • a solvent such as DMSO
  • a palladium catalyst such as (tetrakistriphenylphosphine)palladium(O)
  • Compound of formula (H) is further converted to a compound of formula (J) by reacting with tetra ⁇ «-butylammonium fluoride in the presence of a solvent such as dichloromethane in the temperature range of 0 to 80 0 C.
  • the compounds of formula (I) can also be prepared as per the following general scheme 3.
  • Compound of formula (K) is converted to compound of formula (L) by reacting with the silyl acetylene under Sonogashira reaction conditions using a base such as triethylamine, diisopropylethylamine or the like with a solvent such as DMSO in the presence of a copper catalyst (eg., copper iodide) and a palladium catalyst (eg.,(tetrakistriphenylphosphine) palladium(O)), in the temperature range of room temperature to 100 0 C.
  • a base such as triethylamine, diisopropylethylamine or the like
  • a solvent such as DMSO
  • a copper catalyst eg., copper iodide
  • a palladium catalyst eg.,(tetrakistriphenylphosphine) palladium(O)
  • Compound of formula (L) is converted to a compound of formula (M) by reacting with tetra-r ⁇ - butylammonium fluoride in the presence of a solvent such as dichloromethane in the temperature range of 0 to 80 0 C.
  • Compound of formula (M) is converted to formula (I) by reacting with an appropriately substituted aryl halide under Sonogashira reaction conditions.
  • Compound of formula (I) (when R 3 is O-C(O)-R') can be converted to a hydroxyl compound of formula (I) under general ester hydrolysis conditions known in the art.
  • Step 1 Ethyl 2-bromo-3-cyclopropyl-3-oxopropanoate:
  • Step 2 Ethyl 2-amino-4-cyclopropyl-l,3-thiazole-5-carboxyl ate:
  • Step 4 Ethyl 2- ⁇ [4-(acetyloxy) phenyl] ethynyl ⁇ -4-cyclopropyl-l, 3-thiazole-5-carboxylate:
  • Step 5 4-Cyclopropyl-2-[(4-hydroxyphenyl)ethynyl]-l,3-thiazole-5-carboxylic acid:
  • Step 3 Hydrochloride salt of 2-(4-fluorophenoxy)ethanamine:
  • Step 4 N-[2-(4-Fluorophenoxy)ethyl]-2-iodo-4-methyl-l,3-thiazole-5-carboxamide:
  • step 1 of intermediate-30 By following the similar procedure as described in step-2 of intermediate-30 by using phenol (0.5 g, 5.31 mmoles) and tert-butyl (2-hydroxyethyl) carbamate (step 1, intermediate 30, 1 eq) to get 300 mg of the desired product.
  • Step 3 2-Iodo-4-methyl- ⁇ f-(2-phenoxyethyl)-l,3-thiazole-5-carboxamide:
  • Step 1 iV-5-Benzyl-2-biOmo-4-methyl-l,3-thiazole-5-carboxamide:
  • Step 2 To iV-5-Benzyl-2-iodo-4-methyl-l,3-thiazole-5-carboxamide (100 mg, 0.28 mmoles) (step 1) was added tetra- «-butyl -ammonium fluoride (3 eq) followed by 3-(l- ethynyl)phenylacetate (1 eq) and stirred the reaction mixture at 80 0 C for 3 h. The reaction mixture was then diluted with ethyl acetate and washed with water. The organic layer was then dried over Na 2 SO 4, concentrated and purified by column chromatography to get 45 mg of the desired product.
  • step 1 To iV-5-Benzyl-2-iodo-4-methyl-l,3-thiazole-5-carboxamide (100 mg, 0.28 mmoles) (step 1) was added tetra- «-butyl -ammonium fluoride (3 eq) followed by 3-(l- ethynyl)phenyla
  • step 2 of example 1 The title compound was prepared by following the similar procedure as described in step 2 of example 1, using the product of step 1 of example 1 (100 mg, 0.28 mmoles) and 4-(l- ethynyl) phenylacetate (1 eq) instead of 3-(l-ethynyl) phenylacetate to get 38 mg of the desired product.
  • Step 1 jV-5-(3-Pyridylmethyl)-2-bromo-4-methyl- 1 ,3-thiazole-5-carboxamide:
  • Step 2 By following the similar procedure as described in step 2 of example 1 using iV-5-(3- pyridylmemyl)-2-iodo-4-methyl-l 5 3-thiazole-5-carboxamide (100 mg, 0.28 mmoles) and 4- (l-ethynyl)phenylacetate (1 eq) to get 41 mg of the desired product.
  • the title compound was prepared by following the similar procedure as described in step 2 of example 1, using iV5-(3-pyridylmethyl)-2-iodo-4-methyl-l,3-thiazole-5-carboxamide (100 mg, 0.28 mmoles) and 3-(l-ethynyl) phenylacetate to get 32 mg of the desired product.
  • Step 1 ⁇ r -5-(2-Pyridylmethyl)-2-iodo-4-methyl- 1 ,3-thiazole-5-carboxamide:
  • Step 2 4- ⁇ 2-[4-Methyl-5-(2-pyridylmethylcarbamoyl)-l,3-thiazol-2-yl]-l-ethynyl ⁇ -phenyl acetate:
  • Step 3 N-5-(2-Pyridylmethyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5- carboxamide:
  • Step 1 jV-5-phenethyl-2-iodo-4-rnethyl- 1 ,3-thiazole-5-carboxamide:
  • Step 2 4 [( 4- Methyl -5- ⁇ [(2-phenyl ethyl)amino] -l,3-thiazol-2-yl)-l-ethynyl]-phenyl acetate
  • Step 3 2-[(4-Hydroxy phenyl)ethynyl]-4-methyl-N-(2-phenylethyl)-l ,3-thiazole-5-carbox amide:
  • Step 1 4-[(5- ⁇ [(4-Fluorobenzyl)amino]carbonyl ⁇ -4-methyl-l,3-thiazol-2-yl)ethynyl]phenyl acetate:
  • Step 2 N-(4-Fluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carbox- amide:
  • Step 1 4-[4- Methyl -5 ⁇ [(3-phenylpropyl)amino]carbonyl ⁇ -l,3-thiazol-2-yl)-ethynyl phenyl acetate:
  • Step 1 4-[2- ⁇ 4-Methyl-5-[( ii?)- 1 -phenylethylcarbamoyl]- 1 ,3-thiazol-2-yl ⁇ - 1 -ethynyl)phenyl acetate:
  • Step 2 N-5-[(7i?)-l-Phenylethyl]-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole- 5-carboxamide:
  • Step 1 ' 4-[2- ⁇ 4-Methyl-5-[(16)-l-phenylethylcarbamoyl]-L3-thiazol-2-yl)-l-ethynyl)phenyl acetate:
  • Step 2 7V-5-[(i5)-l-phenylethyl]-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-tliiazole- 5-carboxamide:
  • step 3 example 5 By following the similar procedure as described in step 3 example 5 using 4-[2- ⁇ 4-Methyl-5- [(l ⁇ -l-phenylethylcarbamoylj-l ⁇ -thiazol ⁇ -ylj-l-ethyny ⁇ phenyl acetate (80 mg, 0.2 mmoles) to get 45 mg of the desired product.
  • Step 1 4- [(5- ⁇ [(4-Chlorobenzyl)amino]carbonyl ⁇ -4-methyl- 1 ,3 -thiazol-2-yl)ethynyl] ⁇ henyl acetate:
  • Step 1 4- ⁇ [5-( ⁇ [l-(4-Fluorophenyl)ethyl]amino ⁇ carbonyl)-4-methyl-l,3-thiazol-2-yl] ethynyl ⁇ phenylacetate :
  • Step 2 N-[l-(4-Fluorophenyl)ethyl]-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5- carboxamide:
  • Step 1 4-[(5- ⁇ [(2,4-Difluorobenzyl)amino]carbonyl ⁇ -4-methyl-l,3-thiazol-2-yl)ethynyl] phenylacetate:
  • Step 2 ⁇ V-(2,4-difluorobenzyl)-2- [(4-hydroxyphenyl)ethynyl] -4-methyl- 1 ,3 -thiazole-5 - carboxamide:
  • Step 1 4- ⁇ [5-( ⁇ [2-(4-Fluorophenyl)ethyl]amino ⁇ carbonyl)-4-methyl-l,3-thiazol-2-yl] ethynyl ⁇ phenylacetate :
  • Step 2 N- [2-(4-Fluorophenyl)ethyl] -2-[(4-hydroxyphenyl)ethynyl] -4-methyl- 1 ,3 -thiazole-5 - carboxamide:
  • Step 1 4-[(5- ⁇ [(3-Chlorobenzyl)amino]carbonyl ⁇ -4-methyl-l ,3-thiazol-2-yl)ethynyl]phenyl acetate:
  • Step 2 iV-(3-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carbox- amide:
  • Step 2 2-[(4 ⁇ Hydroxyphenyl)ethynyl]- ⁇ r -(4-methoxybenzyl)-4-methyl- 1 ,3 -thiazole-5- carboxamide:
  • Step_il 4- ⁇ [4-Methyl-5-( ⁇ [4-(trifluoromethyl)benzyl]amino ⁇ carbonyl)-l,3-thiazol-2-yl] ethynyl ⁇ phenylacetate :
  • Step_J2_i 2-[(4-Hydroxyphenyl)ethynyl]-4-methyl-7V-[4-(trifluoromethyl) benzyl] -1,3 -thiazole- 5-carboxamide:
  • Step 1 4-[(5- ⁇ [(2,6-Difluorobenzyl)amino]carbonyl ⁇ -4-methyl- 1 ,3 -thiazol-2-yl)ethynyl] phenylacetate:
  • Step 2 iV-(2,6-Difluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5- carboxamide:
  • Step 1 4- ⁇ 2-[5-(3-Phenylpropylcarbamoyl)-4-trifiuoromethyl-l,3-thiazol-2-yl]-l-ethynyl ⁇ - phenylacetate:
  • Step 2 iV-5-(3-Phenylpropyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifiuoromethyl-l,3- thiazole-5-carboxamide:
  • Step 1 4-[2-(5-Phenethylcarbamoyl-4-trifluoromethyl-l,3-thiazol-2-yl)-l-ethynyl]-phenyl acetate:
  • Step 1 4- ⁇ 2-[5-(4-Fluorobenzylcarbamoyl)-4-trifluoromethyl-l,3-thiazol-2-yl]-l-ethynyl ⁇ - phenylacetate:
  • Step 2 N5-(4-Fluorobenzyl)-2-[2-(4-hydroxyphenyl)-l -ethynyl]-4-trifluoromethyl-l ,3- thiazole-5-carboxamide:
  • Step 1 4-
  • Step 2 JV-5-(4-Trifluoromethvlbenzvl)-2-[ " 2-(4-hvdroxyphenvl)- 1 -ethynyl]-4-trifluorornethyl- 1 ,3-thiazole-5-carboxamide:
  • Step 1 4- ⁇ 2-r5-(4-Methoxybenzylcarbamoyl)-4-trifluoromethyl- 1 ,3 -thiazol-2-yl]- 1 -ethynyl ⁇ - phenylacetate:
  • Step 1 4- ⁇ 2-[5-(Benzylcarbamoyl)-4-trifluoromethyl-l,3-thiazol-2-yl]-l-ethynyl ⁇ -phenyl acetate:
  • Step 2 JV-5-Benzvl-2-r2-(4-hydiOXvphenvl)-l -ethvnvll-4-trifluoromethvl-l .3-thiazole-5- carboxamide:
  • This compound was prepared by following the similar procedure as described in step 'b' of example 28, using 4-[(4-methyl-5- ⁇ [(2-phenoxyethyl)amino]carbonyl ⁇ -l,3-thiazol-2- yl)ethynyl] -phenyl acetate (150 mg, 0.36 mmoles) to get 80 mg of the target compound.
  • the title compound was prepared by following the similar procedure as described in step 3 of example 5 using 4-[(5- ⁇ [(2,4-dichlorobenzyl)amino]carbonyl ⁇ -4-methyl-l,3-thiazol-2- yl)ethynyl]phenylacetate (100 mg, 0.218 mmoles) to get 70 mg of the desired compound.
  • the general values of the compounds in treating diseases or conditions may be established in industry standard animal models for demonstrating the efficacy of compounds described herein in treating the diseases and/or conditions described herein.
  • the compounds of the present invention may be tested for their inhibitory activity for SCD, preferable SCDl, following the procedures known to a person ordinary skill in the art. Therefore, any process for measuring the activity of SCD enzymes including, for example, mouse or human SCD enzymes, may be utilized to assay the activity of the compounds useful in the methods of the present invention in inhibiting said SCD enzymes.
  • the following protocol was employed for testing compounds of the present invention. This protocol is illustrative and is not meant to limit to the scope of the present invention.
  • microsomal SCDl enzyme by the method of Barbara R Talamo et.al Analytical Biochemistry., (1969), 29, 300-304. In this assay the microsomal SCDl enzyme desaturates its substrate (American Radiochemicals) Stearoyl CoA which is tritiated at C9 and ClO positions.
  • Test compounds were dissolved in dimethylsulfoxide and tested at 10 ⁇ M final concentration. Before substrate addition, the test compound or standard reference compound (conjugated linoleic acid at 100 ⁇ M final concentration) were preincubated in reaction buffer with the enzyme for 10 minutes at 30 0 C with shaking. Reaction buffer was essentially as described by Mark G Obukowicz, et ah, JPET, (1998), 287, 157-166, except that the MgCl 2 , ATP (Sigma) and CoA (Sigma) concentrations were changed to 4.9 mM, 7.2 mM and 0.54 mM respectively.
  • the desaturation reaction was initiated by addition of 0.5 ⁇ Ci of 3 H stearoyl CoA and incubated at 37 0 C for 30 minutes with shaking.
  • a control reaction was set without any test compound / reference inhibitor to capture maximum enzymatic activity in the assay. Inhibition of enzyme activity was calculated as a percent of this control reaction giving maximum catalysis. The values are as given in table 1.
  • IC 50 (nM) values of the compounds are set forth in Table 1 wherein “A” refers to an IC 50 value of less than 100 nM, “B” refers to IC 50 value in range of 100.01 - 250 nM, “C” refers to an IC 50 value in range of 250.01 - 500 nM and “D” refers to an IC 50 value of more than 500 nM.
  • Table 1 Compounds ICso (nM) values in ranges:
  • the whole cell based assay was adapted to screen for agents that differentially modulate SCD-I activity present in different tissues.
  • Two cell lines namely human liver cell line (hepatocellular carcinoma HepG2) and human skin cell line (epidermal carcinoma A431) were used.
  • HepG2 cells were seeded in a 24 well plate in complete MEM medium.
  • A431 cells were seeded in a 12 well plate in complete DMEM medium.
  • HepG2 cells were induced with LXR agonist T0901317 in medium containing 4.5 gm/litre glucose and 0.1% fatty acid free BSA for 3 days with media change every day (Wang et ah, Journal of Lipid Research, (2004), 41, 972-980).
  • A431 cells were not induced.
  • the cells were preincubated in plain medium containing 0.1 nM to 10 ⁇ M concentrations of potential SCD-I modulatory compounds for 15 - 30 minutes at 37 °C and further challenged with 0.25 to 7.5 ⁇ Ci tritiated Stearoyl CoA.
  • the cells were incubated for last 6 hours in 5% CO 2 incubator at 37 °C or in specific embodiments for 4 h to 30 h.
  • the incubation medium was collected into tubes.
  • EC 35 was calculated from dose response curve by non linear regression analysis using GraphPadPRISM software. The ratio of EC 35 for skin cells to EC 35 for liver cells was calculated. The EC 35 values for liver and skin cells along with their ratios are given in Tables 2.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides thiazole derivatives as Stearoyl CoA Desaturase (SCD) inhibitors. In particular, the compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase 1 (SCD 1) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase (SCD) inhibitors.

Description

THIAZOLE DERIVATIVES AS STEAROYL CoA DESATURASE INHIBITORS
Related Applications
This application claims the benefit of Indian provisional application numbers 1496/MUM/2008, filed on July 16, 2008; 1881/MUM/2008, filed on Sep 05, 2008; and 2381/MUM/2008, filed on Nov 10, 2008; and U.S. provisional application numbers 61/087,833, filed on Aug 11, 2008; 61/097,268, filed on Sep 16, 2008; and 61/119,436 filed on Dec 03, 2008, all of which are hereby incorporated by reference in their entirety.
Technical Field
The present patent application relates to Thiazole derivatives with SCDl activity.
Background
Metabolic energy balance is important for well-being which is maintained by appropriate adjustment between energy intake and energy expenditure. Primary defects in energy balance produce obesity. Over the past few years there has been a sharp increase in obesity in many countries. Obesity is a principal cause of morbidity and mortality mainly because it increases risk for other conditions that shorten life, including diabetes, insulin resistance, coronary artery disease, hypertension and non-alcoholic fatty liver disease collectively known as metabolic syndrome (J Am. Med. Assoc, (2002), 288, 1723-1727). Obesity has been identified as an independent risk factor for the development of type 2 diabetes.
Although the exact etiology of many events underlying obesity is not very well known, typically obesity is manifested by increase in plasma free fatty acids and excessive lipid accumulation in some organs. Abnormal lipid metabolism in obese subjects results in accumulation of significant amounts of fat in liver, adipose tissue, muscle and other peripheral tissues which sets in insulin resistance {Obesity Reviews, (2005), 6, 169-174). In the liver, fatty acids accumulate causing an increase in hepatic lipid content or get packaged into the very low density lipoprotein for export to other peripheral tissues. Liver steatosis associated with obesity can also result from an enhanced rate of de novo fatty acid synthesis and/or dysregulation of intracellular lipid partitioning in which fatty acid oxidation is impaired and its esterification enhanced. Lipid abnormalities in obese subjects, in particular hypertriglyceridemia, low HDL cholesterol and altered LDL cholesterol particle size, are atherogenic. The dyslipidemic state initiates a cascade of events including release of proinflammatory adipokines which induces a proinflammatory state that drives pathogenesis of atherosclerosis. Increased release of proinflammatory adipokines also increases fibrinogen and plasminogen activator inhibitor levels thereby increasing risk for arterial thrombosis. Several studies show that even modest weight gain can precipitate the onset of hypertension (Ann. Rev. Med, (2005), 56, 45-62). Hence obesity alone can drive all aspects of the metabolic syndrome. It is believed that effective treatment of obesity could lead to prevention and control of metabolic syndrome (Obesity Reviews, (2005), 6, 169-174).
Stearoyl CoA desaturase 1 (SCDl) is shown to be a key enzyme that plays crucial role in lipid metabolism and body weight control (Science, (2002), 297, 240-243; Obesity Reviews, (2005), 6, 169-174; J Clinical Investigation, (2005), 1-9). SCDl is a central lipogenic enzyme catalyzing the biosynthesis of monounsaturated fatty acids from saturated fatty acids by addition of a cis double bond between carbon 9 and carbon 10 (Pr oc. Natl. Acad. ScI, (1974), 71, 4565-4569; J Biol Chem., (1976), 25j_, 5095-5103). SCDl has two preferred substrates palmitoyl and stearoyl CoA, which are desaturated to palmitoleoyl and oleoyl CoA respectively (J Biol Chem., 25_i, 5095-5103 (1976)). Oleate is found to be the major monounsaturated fatty acid of membrane phospholipids, triglycerides, cholesterol esters, wax esters and alkyl-1, 2-diacylglycerol. The ratio of stearate to oleate is one of the factors influencing membrane fluidity and its alteration is important in diseases like aging, cancer, diabetes, obesity, and neurological, vascular and heart diseases (Biochem. Biophys. Acta., (1976), 431, 469-480; J Biol. Chem., (1993), 268, 6823-6826; Diabetes, (1991), 40, 280-289; Neurochem Res., (1994), 26, 771-782; Arthritis Rheum., (2000), 43, 894-900; Cancer Lett., (2001), 173, 139-144).
The role of SCDl in regulation of body weight is well discussed in the literature. Robust up-regulation of SCDl expression and/or activity is observed in obese experimental animals (Science, (2002), 297, 240-243), fat chickens (Am. Soc Nutri Scie., 249-256 (1997)) and obese human subjects (Cell Metάb., (2005), Z1 251-61) compared to their lean counterparts. In chickens, the fat chickens have higher hepatic delta-9 desaturase activity and higher plasma triglyceride compared to lean birds. Inhibition of delta-9 desaturase by a mixture of cyclopropenic fatty acids resulted in reduced triglyceride formation in vitro in hepatocytes isolated from the fat chickens (Am. Soc Nutri Scie., (1997), 249-256). SCDl over activity leads to weight gain and its deficiency leads to leanness. SCDl deficiency either directly or indirectly induces a signal that partitions fatty acids towards oxidation rather than synthesis. Asebia mice with natural mutation in the SCDl gene manifest defective cholesterol ester and triglyceride synthesis and are lean and hypermetabolic (J Biol. Chem., (2000), 275, 30132-30138; Science, (2002), 29L 240-243). Laboratory mice with targeted disruption in the SCDl gene are resistant to diet-induced obesity and have reduced body adiposity, liver lipid accumulation and postprandial plasma insulin and glucose levels, with concomitant increase in the metabolic rate, thermogenesis and insulin sensitivity (J Nutr., (2001), 131, 2260-2268; PNAS, (2002), 99, 11482-11486). SCDl is documented as a key enzyme in regulating hepatic lipogenesis and lipid oxidation and therapeutic manipulation of SCD can be of benefit in treatment of obesity and metabolic syndrome (Obesi. Reviews, J)1 169-174 (2005); Curr. Drug Targets Immune Endocr Metabol Disord., (2003), 3, 271-280). Several studies report inhibition of SCDl expression and activity by different agents such as thia- fatty acids like 9-thiastearic acid, cyclopropenoid fatty acids like sterculic acid and certain conjugated linoleic acid isomers. Trans-10, cis-12 isomer of conjugated linolenic acid inhibits SCDl expression as well as desaturase activity in vitro (Biochim Biophys Acta., (2000), 1486 (2-3). 285-292; Biochem Biophys Res Commun., (2001), 284 689-693). Conjugated linoleic acid (CLA) administration through feed reduces body fat and increases lean body mass in several animal species {Lipids, (1997), 32^ 853-858; FASEB, U^ A836 (1998); Lipids, (1999), 34, 243- 248). Sterculic acid (8-(2-octylcyclopropenyl) octanoic acid) and malvalic acid (7- (2-octylcyclopropenyl)heptanoic acid) are Cl 8 and Cl 6 derivatives of sterculoyl and malvaloyl fatty acids, respectively and inhibit SCD enzymatic activity by direct interaction with the enzyme. However all these agents are weak and non-specific inhibitors of SCDl. SCDl antisense oligonucleotide inhibitors specifically reduce SCDl expression thereby reducing fatty acid synthesis and secretion, body adiposity, hepatomegaly, steatosis and prevent obesity in mice by improving energy balance (J Clinical Investigation., (2005) F 1- 9).
US 2006/009459 and WO 2005/011653, WO 2005/01164, WO 2005/011655, WO 2005/011656 and WO 2005/011657 disclose certain pyridazine derivatives, pyridyl derivatives, and piperazine derivatives and their use for inhibiting human stearoyl-CoA desaturase (hSCD) activity. US 2004/072877 is directed to a method for increasing insulin sensitivity by reducing stearoyl CoA desaturase 1 (SCDl) activity in a subject sufficiently to increase insulin sensitivity. There is still a need for safer and more effective therapeutic treatments for diseases, conditions and/or disorders modulated by SCDl . In particular, there is a need for novel compounds that are used for treating obesity, diabetes, cardiovascular disease and complications thereof.
Summary
The present invention provides Thiazole compounds as SCDl inhibitors, which are used in the treatment of diseases, conditions or disorders modulated by SCDl, and processes for the synthesis of these compounds.
In one aspect, the compound of the present invention is
Figure imgf000005_0001
wherein,
R is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted cycloalkyl;
R1 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkyl, fully or partially substituted haloalkyl, substituted or unsubstituted haloalkyloxy, fully or partially substituted haloalkyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, or substituted or unsubstituted heteroaryl;
R2 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl; wherein substituents are independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkyl, fully or partially substituted haloalkyl, substituted or unsubstituted haloalkyloxy, fully or partially substituted haloalkyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, or substituted or unsubstituted heteroaryl; at each occurrence R3 is independently selected from hydrogen, hydroxyl, cyano, nitro, halogen, acetyl, acetoxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cyclcoalkylalkyl, substituted or unsubstituted cyclcoalkyloxy, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxyalkyl, substituted or unsubstituted alkoxyaryl, substituted or unsubstituted arylalkyl, -0-C(O)-R', -C(0)NRaRb, -SONRaRb, -SO2NRaRb, -ORa, -COORa, -C(0)Ra, -C(S)R3, -C(O)ONRaRb, -NRaC(O)ORb, - NRaRb, -NRaC(0)Rb, or -NRaC0NRaRb; at each occurrence Ra and Rb are same or different and are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl;
R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl;
'n' is an integer selected from 1 to 5, both inclusive;
L is (C1-C6) alkylene linker which may be further substituted with halogen or alkyl.
It should be understood that the formula (I) structurally encompasses all prodrugs, stereoisomers, including enantiomers and diastereomers, and pharmaceutically acceptable salts that may be contemplated from the chemical structure of the genus described herein.
According to one embodiment, specifically provided are compounds of the formula (I) in which L is -CH2-, -CH2-CH2-, -CH2-CH2-CH2-, -CH(-CH3)-, or alkoxy (-0-CH2- CH2-).
According to another embodiment, specifically provided are compounds of the formula (I) in which R is hydrogen. According to another embodiment, specifically provided are compounds of the formula (I) in which Ri is substituted or unsubstituted alkyl, preferably methyl.
According to another embodiment, specifically provided are compounds of the formula (I) in which R1 is substituted or unsubstituted cycloalkyl (eg., cyclopropyl), fully or partially substituted haloalkyl (eg., trifluoroalkyl).
According to another embodiment, specifically provided are compounds of the formula (I) in which R2 is substituted or unsubstituted aryl; wherein aryl is preferably unsubstituted phenyl.
According to another embodiment, specifically provided are compounds of the formula (I) in which R2 is substituted or unsubstituted aryl; wherein aryl is preferably mono substituted phenyl. In this embodiment, substituent is halogen (eg., fluorine, chlorine), alkoxy (eg., methoxy) or haloalkyl (eg., trifluoroalkyl).
According to another embodiment, specifically provided are compounds of the formula (I) in which R2 is substituted or unsubstituted aryl; wherein aryl is preferably di or tri substituted phenyl. In this embodiment, substituents are independently selected from halogen (eg., fluorine, chlorine or bromine).
According to another embodiment, specifically provided are compounds of the formula (I) in which R2 is substituted or unsubstituted heteroaryl, preferably pyridine.
According to another embodiment, specifically provided are compounds of the formula (I) in which R3 is independently selected from fluoro, hydroxy, methyl, ethyl, trifluoromethyl, or triflouoromethoxy; preferably hydroxy. In this embodiment, 'n' is 1 or 2.
Representative examples of compounds of the present invention are provided below. These compounds are illustrative in nature only and do not limit the scope of the invention. iV-5-Benzyl-2-[2-(3-hydroxyphenyl)- 1 -ethynyl]-4-methyl- 1 ,3-thiazole-5-carboxamide; N-5-Benzyl-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5-carboxamide; jV-5-(3-Pyridylmethyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5- carboxamide;
N-5-(3-Pyridylmethyl)-2-[2-(3-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5- carboxamide; iV-5-(2-Pyridylmethyl)-2-[2-(4-hydroxyphenyl)- 1 -ethynyl]-4-methyl- 1 ,3-thiazole-5- carboxamide;
2-[(4-Hydroxy phenyl) ethynyl]- 4 -methyl- N - (2-phenyl ethyl)- l,3thiazole-5-carboxamide; iV-(4-Fluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl l,3-thiazole-5-carboxamide; 2-[(4-Hydroxyphenyl)ethynyl]-4-methyl-iV-(3-phenylpropyl)-l,3-thiazole-5-carboxaniide;
Λr-5-[(J/i?)-l-Phenylethyl]-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5- carboxamide;
N-5 -[(1S)- 1 -Phenylethyl] -2- [2-(4-hydroxyphenyl)- 1 -ethynyl] -4-methyl- 1 ,3 -thiazole-5- carboxamide; jV-(4-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide;
N-[I -(4-Fluorophenyl)ethyl] -2- [(4-hy droxyphenyl)ethynyl] -4-methyl- 1 , 3 -thiazole-5 - carboxamide; jV-(2,4-Difluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide;
N-[2-(4-Fluorophenyl)ethyl]-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5- carboxamide;
N-(3-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide; 2-[(4-Hydroxyphenyl)ethynyl]-iV-(4-methoxybenzyl)-4-methyl-l,3-thiazole-5-carboxamide;
2-[(4-Hydroxyphenyl)ethynyl]-4-methyl-iV-[4-(trifluoromethyl)benzyl]-l,3-thiazole-5- carboxamide;
7V-(2,6-Difluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide; N-(2-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide;
7V-5-(3-Phenylpropyl)-2-[2-(4-hydroxyphenyl)- 1 -ethynyl]-4-trifluoromethyl- 1 ,3-thiazole-5- carboxamide;
N-5-Phenethyl-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3-thiazole-5- carboxamide;
Λr-5-(4-Fluorobenzyl)-2- [2-(4-hydroxyphenyl)~ 1 -ethynyl] -4-trifluoromethyl- 1 ,3 -thiazole-5- carboxamide; Λr-5-(4-Trifluoromethylbenzyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3- thiazole-5 -carboxamide ;
N-5-(4-Methoxybenzyi)-2-[2-(4-hydroxyphenyl)- 1 -ethynyl]-4-trifluoromethyl- 1 ,3-thiazole-5- carboxamide; iV-5-Benzyl-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3-thiazole-5- carboxamide;
4-Cyclopropyl-2-[(4-hydroxyphenyl) ethynyl]-iV-phenyl propyl-l,3-thiazole-5-carboxamide;
4-Cyclopropyl-iV-(4-fluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-l,3-thiazole-5- carboxamide; iV-[2-(4-Fluorophenoxy)ethyl]-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5- carboxamide;
2- [(4-Hydroxyphenyl)ethynyl] -4-methyl-iV-(2-phenoxy ethyl)- 1 ,3 -thiazole- 5 -carboxamide ; and iV-(2,4-Dichlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide or prodrugs, such as those with linkages -OCO- (oxycarbonyl), -OCOO- etc. at the phenolic hydroxyl group, pharmaceutically acceptable salts thereof, stereoisomers thereof, of compounds 1 to 30 are also contemplated.
In another aspect, provided herein is a pharmaceutical composition comprising a therapeutically effective amount of one or more compounds of Formula (I) and optionally one or more pharmaceutically acceptable excipients, carriers, diluents or mixture thereof.
In another aspect, provided herein is a method for preventing, ameliorating or treating a disease, disorder or syndrome modulated by SCDl in a subject comprising administering to the subject in need thereof a therapeutically effective amount of one or more compounds of Formula (I), or a pharmaceutical composition as described herein.
In another aspect, there is provided a method of inhibiting lipid metabolism that proceeds via a Stearoyl-CoA Desaturase-1 (SCDl) mediated pathway in a subject, the method including administering to the subject in need thereof a therapeutically effective amount of one or more compounds of Formula I, that exhibits increased SCDl inhibitory activity in a target tissue in comparison with SCDl activity in a reference tissue.
Preferably, in the method according to the above aspect, the target and reference tissues are selected from liver and skin. In one preferred variant, the target tissue is liver and the reference tissue is skin. While the invention is not limited by any specific theory, the selective SCDl inhibitor is believed to decrease conversion of saturated fatty acids to unsaturated fatty acids in liver cells to a greater extent than in skin cells. The preferred fatty acids are selected from palmitoyl CoA and stearoyl CoA.
In one variant in accordance with the above aspects, the subject is a cell. In another variant, the subject is a mammal, preferably, a human.
For SCD-I inhibitors selective for liver, the preferred ratio of EC35 for the SCD-I inhibitor in skin cells to that in liver cells is greater than 1.
In yet another aspect, provided herein are processes for preparing compounds of the present invention.
Detailed Description The following definitions apply to terms as used herein:
The terms "halogen" or "halo" includes fluorine, chlorine, bromine, or iodine.
The term "alkyl" refers to hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to eight carbon atoms, and which is attached to the rest of the molecule by a single bond, e.g., methyl, ethyl, n-propyl, 1- methylethyl (isopropyl), n-butyl, «-pentyl, and 1,1-dimethylethyl (tert-bntyϊ). The term "Cj-6 alkyl" refers to an alkyl chain having 1 to 6 carbon atoms. Unless set forth or recited to the contrary, all alkyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
The term "alkenyl" refers to an hydrocarbon chain containing from 2 to 10 carbon atoms and including at least one carbon-carbon double bond. Non-limiting examples of alkenyl groups include ethenyl, 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-l- propenyl, 1-butenyl, and 2-butenyl. Unless set forth or recited to the contrary, all alkenyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
The term "alkynyl" refers to a hydrocarbyl radical having at least one carbon-carbon triple bond, and having 2 to about 12 carbon atoms (with radicals having 2 to about 10 carbon atoms being preferred). Non-limiting examples of alkynyl groups include ethynyl, propynyl, and butynyl. Unless set forth or recited to the contrary, all alkynyl groups described or claimed herein may be straight chain or branched, substituted or unsubstituted. The term "alkylene" refers to divalent of alkyl group, wherein alkyl is as defined above.
The term "haloalkyl" is used to denote a group comprised of an alkyl group substituted with halogen atom, where alkyl group is as defined above and halogen is used to denote fluorine, chlorine, bromine or iodine, an example of such group is trifluoromethyl, difluoromethyl.
The term "alkoxy" denotes an alkyl group attached via an oxygen linkage to the rest of the molecule. Representative examples of such groups are -OCH3 and -OC2H5. Unless set forth or recited to the contrary, all alkoxy groups described or claimed herein may be straight chain or branched, substituted or unsubstituted.
The term "haloalkoxy" unless otherwise specified refers to an haloalkyl group attached via an oxygen linkage to the rest of the molecule. Representative examples of such groups are -OCF3 and -OC2Fs.
The term "cycloalkyl" denotes a non-aromatic mono or multicyclic ring system of 3 to about 12 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Examples of multicyclic cycloalkyl groups include, but are not limited to, perhydronapththyl, adamantyl and norbornyl groups, bridged cyclic groups or sprirobicyclic groups, e.g., sprio(4,4)non-2-yl. Unless set forth or recited to the contrary, all cycloalkyl groups described or claimed herein may be substituted or unsubstituted.
The term "cycloalkylalkyl" refers to a cyclic ring-containing radical having 3 to about 8 carbon atoms directly attached to an alkyl group. The cycloalkylalkyl group may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure. Non-limiting examples of such groups include cyclopropylmethyl, cyclobutylethyl, and cyclopentylethyl. Unless set forth or recited to the contrary, all cycloalkylalkyl groups described or claimed herein may be substituted or unsubstituted.
The term "cycloalkenyl" refers to a cyclic ring-containing radical having 3 to about 8 carbon atoms with at least one carbon-carbon double bond, such as cyclopropenyl, cyclobutenyl, and cyclopentenyl. Unless set forth or recited to the contrary, all cycloalkenyl groups described or claimed herein may be substituted or unsubstituted.
The term "aryl" refers to an aromatic radical having 6 to 14 carbon atoms, including monocyclic, bicyclic and tricyclic aromatic systems, such as phenyl, naphthyl, tetrahydronapthyl, indanyl, and biphenyl. Unless set forth or recited to the contrary, all aryl groups described or claimed herein may be substituted or unsubstituted.
The term "arylalkyl" refers to an aryl group as defined above directly bonded to an alkyl group as defined above, e.g., -CH2C6H5 and -C2H5C6H5.
The term "heterocyclyl" and "heterocyclic ring" "heterocyclic group" refers to a stable 3- to 15-membered ring radical which consists of carbon atoms and from one to five heteroatoms selected from nitrogen, phosphorus, oxygen and sulfur. For purposes of this invention, the heterocyclic ring radical may be a monocyclic, bicyclic or tricyclic ring system, which may include fused, bridged or spiro ring systems, and the nitrogen, phosphorus, carbon, oxygen or sulfur atoms in the heterocyclic ring radical may be optionally oxidized to various oxidation states. In addition, the nitrogen atom may be optionally quaternized; and the ring radical may be partially or fully saturated (i.e., heterocyclic or heteroaryl). Examples of such heterocyclic ring radicals include, but are not limited to, azetidinyl, acridinyl, benzodioxolyl, benzodioxanyl, benzofuranyl, carbazolyl, cinnolinyl, dioxolanyl, indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pyridyl, pteridinyl, purinyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazolyl, imidazolyl, tetrahydroisoquinolinyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl, indanyl, isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolinyl, thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl, benzooxazolyl, furyl, tetrahydrofuranyl, tetrahydropyranyl, thienyl, benzothienyl, thiamorpholinyl, thiamorpholinyl sulfoxide, thiamoφholinyl sulfone, dioxaphospholanyl, oxadiazolyl, chromanyl, and isochromanyl. The heterocyclic ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heterocyclyl groups described or claimed herein may be substituted or unsubstituted, including those included in more complex substructures.
The term "heteroaryl" refers to an aromatic heterocyclic ring radical. The heteroaryl ring radical may be attached to the main structure at any heteroatom or carbon atom that results in the creation of a stable structure. Unless set forth or recited to the contrary, all heteroaryl groups described or claimed herein may be substituted or unsubstituted, including those included in more complex substructures.
The term "heterocyclylalkyl" refers to a heterocyclic ring radical directly bonded to an alkyl group. The heterocyclylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure.
The term "heteroarylalkyl" refers to a heteroaryl ring radical directly bonded to an alkyl group. The heteroarylalkyl radical may be attached to the main structure at any carbon atom in the alkyl group that results in the creation of a stable structure.
Unless otherwise specified, the term "substituted" as used herein refers to a group or moiety having one or more of the substituents attached to the structural skeleton of the group or moiety, including, but not limited to such substituents as hydroxy, halogen, carboxyl, cyano, nitro, oxo (=0), thio (=S), substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclic ring, substituted or unsubstiuted guanidine, -COORX, -C(O)R*, -C(S)RX, -C(0)NRxRy, - C(0)0NRxRy, -NRxCONRyRz, -N(Rx)SORy, -N(Rx)SO2Ry, -(=N-N(Rx)Ry), -NRxC(0)0Ry, - NRxRy, -NRxC(O)Ry, -NRxC(S)Ry, -NRxC(S)NRyRz, -S0NRxRy, -SO2NRxRy, -ORX, -ORxC(O)NRyRz, -ORxC(O)ORy, -OC(O)RX, -0C(0)NRxRy, -RxNRyC(O)Rz, -RxORy, -RxC(O)ORy, -RxC(O)NRyRz, -RxC(O)Ry, -RxOC(O)Ry, -SRX, -SORX, -SO2RX, and -ONO2, wherein Rx, Ry and Rz are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted amino, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted heterocyclylalkyl ring, substituted or unsubstituted heteroarylalkyl, or substituted or unsubstituted heterocyclic ring. The substituents in the aforementioned "substituted" groups cannot be further substituted. For example, when the substituent on "substituted alkyl" is "substituted aryl", the substituent on "substituted aryl" cannot be "substituted alkenyl". The term "analog" refers to a compound that is a structural derivative of a parent compound that differs from it by a single element.
The term "prodrug" refers to a compound that is transformed in vivo to yield a compound of formula (I) or a pharmaceutically acceptable salt, hydrate or solvate of the compound. The transformation may occur by various mechanisms, such as through hydrolysis in blood. A discussion of the use of prodrugs is provided by T. Higuchi and W. Stella, "Pro-drugs as Novel Delivery Systems,1" Vol. !_4 of the A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, ed Edward B. Roche, American Pharmaceutical Association and Pergamon Press, (1987).
The term "inhibiting lipid metabolism that proceeds via an SCD-I -mediated pathway" denotes alteration in normal functioning of lipid metabolic pathway that involves SCD-I enzyme, including, particularly, a decrease in lipid formation via a pathway facilitated by the SCD-I enzyme.
The term "selective SCD-I inhibitor" denotes a substance that affects activity of SCD-I enzyme in a differential manner, particularly, a substance that selectively affects SCD activity in one tissue type as compared to SCD-I activity of the same substance in another tissue type. For instance, a substance is a selective SCD-I inhibitor if the SCD-I inhibitory activity of the substance in target tissue is greater than SCD-I inhibitory activity of the substance in reference tissue. An agent may be a selective inhibitor for liver SCD-I by having a lower EC35 in liver cells than in skin cells.
The term "target tissue" with respect to SCD-I activity denotes a tissue type in which SCD-I inhibition is intended to be exerted via administration of a substance having SCD-I inhibitory activity. Non-limiting examples of "target tissue" include liver, skin and cornea.
The term "reference tissue" with respect to SCD-I activity denotes a tissue type in which SCD-I inhibition is not intended to be exerted via administration of a substance having SCD-I inhibitory activity. Non-limiting example of a "reference tissue" include liver, skin and cornea.
The term EC35 refers to the concentration of the compound which inhibits the activity of the enzyme halfway between the baseline and maximum response of approximately 70%.
The term IC50 refers to the concentration of inhibitor that reduces enzyme activity by 50%.
The term "treating" or "treatment" of a state, disorder or condition includes: (a) preventing or delaying the appearance of clinical symptoms of the state, disorder or condition developing in a subject that may be afflicted with or predisposed to the state, disorder or condition but does not yet experience or display clinical or subclinical symptoms of the state, disorder or condition; (b) inhibiting the state, disorder or condition, i.e., arresting or reducing the development of the disease or at least one clinical or subclinical symptom thereof; or (c) relieving the disease, i.e., causing regression of the state, disorder or condition or at least one of its clinical or subclinical symptoms.
The term "subject" includes mammals (especially humans) and other animals, such as domestic animals (e.g., household pets including cats and dogs) and non-domestic animals (such as wildlife).
A "therapeutically effective amount" means the amount of a compound that, when administered to a subject for treating a state, disorder or condition, is sufficient to cause the effect in the subject which is the purpose of the administration. The "therapeutically effective amount" will vary depending on the compound, the disease and its severity and the age, weight, physical condition and responsiveness of the subject to be treated.
Pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic bases (such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, and Mn), salts of organic bases (such as N,N'-diacetylethylenediamine, glucamme, triethylamine, choline, hydroxide, dicyclohexylamine, metformin, benzylamine, trialkylamine, and thiamine), salts of chiral bases (such as alkylphenylamine, glycinol, and phenyl glycinol), salts of natural amino acids (such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, and serine), salts of non-natural amino acids (such as D-isomers or substituted amino acids), salts of guanidine, salts of substituted guanidine (wherein the substituents are selected from nitro, amino, alkyl, alkenyl, or alkynyl), ammonium salts, substituted ammonium salts, and aluminum salts. Other pharmaceutically acceptable salts include acid addition salts (where appropriate) such as sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates (such as trifluoroacetate), tartrates, maleates, citrates, fumarates, succinates, palmoates, methanesulphonates, benzoates, salicylates, benzenesulfonates, ascorbates, glycerophosphates, and ketoglutarates. Yet other pharmaceutically acceptable salts include, but are not limited to, quaternary ammonium salts of the compounds of invention with alkyl halides or alkyl sulphates (such as MeI or Me2SO4). Compounds described herein can comprise one or more asymmetric carbon atoms and thus can occur as racemic mixtures, enantiomers and diastereomers. These compounds can also exist as conformers/rotamers. All such isomeric forms and/or regiomers of these compounds are expressly included in the present invention, Although the specific compounds exemplified in this application may be depicted in a particular stereochemical configuration, compounds having either the opposite stereochemistry at any given chiral centre are envisioned as a part thereof.
Pharmaceutical Compositions
The pharmaceutical composition of the present invention comprises one or more compounds described herein and one or more pharmaceutically acceptable excipients, carriers, diluents or mixture thereof. The compounds described herein may be associated with one or more pharmaceutically acceptable excipients, carriers, diluents or mixture thereof in the form of capsule, sachet, paper or other container.
Examples of suitable carriers include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, polyhydroxyethoxylated castor oil, peanut oil, olive oil, gelatin, lactose, terra alba, sucrose, dextrin, magnesium carbonate, sugar, cyclodextriri, amylose, magnesium stearate, talc, gelatin, agar, pectin, acacia, stearic acid or lower alkyl ethers of cellulose, silicic acid, fatty acids, fatty acid amines, fatty acid monoglycerides and diglycerides, pentaerythritol fatty acid esters, polyoxyethylene, hydroxymethyl cellulose and polyvinylpyrrolidone.
The carrier or diluent may include a sustained release material, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
The pharmaceutical composition may also include one or more pharmaceutically acceptable auxiliary agents, wetting agents, emulsifying agents, suspending agents, preserving agents, salts for influencing oxmetic pressure, buffers, sweetening agents, flavouring agents, colorants, or any combination of the foregoing. The pharmaceutical composition of the invention may be formulated so as to provide quick, sustained, or delayed release of the active ingredient after administration to the subject by employing methods known in the art.
The pharmaceutical compositions of the present invention may be prepared by conventional techniques, e.g., as described in Remington: The Science and Practice of Pharmacy, 20th Ed., 2003 (Lippincott Williams & Wilkins). For example, the active compound is mixed with a carrier, or diluted by a carrier, or enclosed within a carrier, which may be in the form of an ampoule, capsule, sachet, paper, or other container. When the carrier serves as a diluent, it may be a solid, semi-solid, or liquid material that acts as a vehicle, excipient, or medium for the active compound. The active compound is adsorbed on a granular solid container, for example, in a sachet.
The pharmaceutical compositions may be in conventional forms, for example, capsules, tablets, aerosols, solutions, suspensions or products for topical application.
The route of administration may be any route which effectively transports the active compound of the invention to the appropriate or desired site of action. Suitable routes of administration include, but are not limited to, oral, nasal, pulmonary, buccal, subdermal, intradermal, transdermal, parenteral, rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic (such as with an ophthalmic solution) or topical (such as with a topical ointment). The oral route is preferred.
Solid oral formulations include, but are not limited to, tablets, capsules (soft or hard gelatin), dragees (containing the active ingredient in powder or pellet form), troches and lozenges. Tablets, dragees, or capsules having talc and/or a carbohydrate carrier or binder or the like are particularly suitable for oral application. Preferable carriers for tablets, dragees, or capsules include lactose, cornstarch, and/or potato starch. A syrup or elixir is used in cases where a sweetened vehicle is employed.
Liquid formulations include, but are not limited to, syrups, emulsions, soft gelatin and sterile injectable liquids, such as aqueous or non-aqueous liquid suspensions or solutions.
For parenteral application, particularly suitable are injectable solutions or suspensions, preferably aqueous solutions with the active compound dissolved in polyhydroxylated castor oil.
Suitable doses of the compounds for use in treating the diseases and disorders described herein can be determined by those skilled in the relevant art. Therapeutic doses are generally identified through a dose ranging study in humans based on preliminary evidence derived from the animal studies. Doses must be sufficient to result in a desired therapeutic benefit without causing unwanted side effects. Mode of administration, dosage forms, suitable pharmaceutical excipients, diluents or carriers can also be well used and adjusted by those skilled in the art. AU changes and modifications are envisioned within the scope of the present invention. Methods of Treatments
The present invention further provides a method of treating a disease, condition or disorder modulated by a stearoyl CoA desaturase, especially those modulated by SCDl, in a subject by administering to the subject in need thereof a therapeutically effective amount of a compound or a pharmaceutical composition described herein.
Diseases, conditions, and disorders that are modulated by a stearoyl CoA desaturase, include, but are not limited to, diabetes, diabetes related syndromes, disorders or diseases obesity, obesity related diseases, conditions, and disorders, cardiovascular diseases (such as atherosclerosis), hepatic steatosis and other metabolic syndromes, metabolism related syndromes, disorders and diseases, and non-alcoholic fatty liver disease.
SCD, particularly human SCD, can be regulated to treat obesity. Obesity and overweight are defined as an excess of body fat relative to lean body mass. An increase in caloric intake or a decrease in energy expenditure or both can bring about this imbalance leading to surplus energy being stored as fat. In contrast, anorexia and cachexia are characterized by an imbalance in energy intake versus energy expenditure leading to a negative energy balance and weight loss. Agents that either increase energy expenditure and/or decrease energy intake, absorption or storage would be useful for treating obesity, overweight, and associated comorbidities. Agents that increase energy intake and/or decrease energy expenditure or increase the amount of lean tissue would be useful for treating cachexia, anorexia, and wasting disorders. An SCD gene, translated proteins and agents which modulate the gene or portions of the gene or its products are useful for treating obesity, overweight, anorexia, cachexia, wasting disorders, appetite suppression, appetite enhancement, increases or decreases in satiety, modulation of body weight, and/or other eating disorders such as bulimia. Accordingly, diseases, conditions, and disorders that are modulated by a stearoyl CoA desaturase, include, but are not limited to, obesity, overweight, anorexia, cachexia, wasting disorders, appetite suppression, appetite enhancement, and other eating disorders such as bulimia. Furthermore, the compounds of the present invention increase or decrease in satiety and modulate body weight.
Obesity related syndromes, disorders and diseases include, but are not limited to, obesity as a result of (i) genetics, (ii) diet, (iii) food intake volume, (iv) a metabolic disorder, (v) a hypothalmic disorder, (vi) age, (vii) abnormal adipose mass distribution, (viii) abnormal adipose compartment distribution, (ix) compulsive eating disorders, and (x) motivational disorders which include the desire to consume sugars, carbohydrates, alcohols or drugs or any ingredient with hedonic value. Symptoms associated with obesity related syndromes, disorders, and diseases include, but are not limited to, reduced activity. Obesity also increases the likelihood of sleep apnea, gallstones, osteoporosis and ceratin cancers.
Diabetes related syndromes, disorders and diseases include, but are not limited to, glucose dysregulation, insulin resistance, glucose intolerance, hyperinsulinemia, dyslipidemia, hypertension, obesity, and hyperglycemia.
Cardiovascular diseases include, but are not limited to, (i) coronary artery disease, (ii) atherosclerosis, (iii) heart disease, (iv) hypercholesterolemia, (v) hypertriglyceridemia, (vi) hypertriglyceridemia secondary to another disorder or disease (such as hyperlipoproteinemias), (vii) hyperlipidemia, (viii) disorders of serum levels of triglycerides, VLDL, HDL, and LDL, (ix) cholesterol disorders, (x) cerebrovascular disease (including but not limited to, stroke, ischemic stroke and transient ischemic attack (TIA)), (xi) peripheral vascular disease, and (xii) ischemic retinopathy.
Metabolism related syndromes, disorders or diseases include, but are not limited to, (i) metabolic syndrome, (ii) dyslipidemia, (iii) elevated blood pressure, (iv) insulin sensitivity or resistance, (v) type II diabetes, (vi) type I diabetes, (vii) diabetic complications, (viii) increased abdominal girth, (ix) glucose tolerance, (x) microalbuminemia, (xi) hyperuricaemia, (xii) hyperinsulinemia, (xiii) hypercholesterolemia, (xiv) hyperlipidemias, (xv) atherosclerosis, (xvi) hypertriglyceridemias, (xvii) arteriosclerosis and other cardiovascular diseases, (xviii) osteoarthritis, (xix) dermatological diseases, (xx) sleep disorders (e.g., disturbances of circadian rhythm, dysomnia, insomnia, sleep apnea and narcolepsy), (xxi) cholelithiasis, (xxii) hepatomegaly, (xxiiii) steatosis, (xxiv) syndrome X, (xxv) abnormal alanine aminotransferase levels, (xxvi) polycystic ovarian disease, and (xxvii) inflammation.
In a preferred embodiment, compounds of the invention will, in a subject, increase HDL levels and/or decrease triglyceride levels and/or decrease LDL or non-HDL-cholesterol levels. In another embodiment, compounds of the invention will, in a subject, increase body lean mass and decrease obesity. In another embodiment, compounds of the invention will, in a subject, decrease hepatic steatosis.
Methods described herein can also include one or more of the following embodiments. For example, in one embodiment, the diseases, disorders, and syndromes are selected, but are not limited to, obesity, for example, obesity resulting from genetics, diet, food intake volume, a metabolic disorder, a hypothalmic disorder, age, abnormal adipose mass distribution, abnormal adipose compartment distribution, compulsive eating disorders, motivational disorders, which include the desire to consume sugars, carbohydrates, alcohols or drugs or any ingredient with hedonic value, reduced activity or combination thereof; overweight conditions; anorexia; bulimia; cachexia; dysregulated appetite; or obesity related diseases, disorders, and symptoms; diabetes (including Type I and Type II diabetes); diabetic complications; glucose tolerance; hyperinsulinemia; insulin sensitivity or resistance; hepatic steatosis; increased abdominal girth; metabolic syndrome; cardiovascular diseases including, for example, atherosclerosis, dyslipidemia, elevated blood pressure, microalbuminemia, hyperuricaemia, hypercholesterolemia, hyperlipidemias, atherosclerosis, hypertriglyceridemias, arteriosclerosis or combination thereof; osteoarthritis; dermatological diseases; sleep disorders including, for example, disturbances of circadian rhythm, dysomnia, insomnia, sleep apnea, narcolepsy or combination thereof; cholelithiasis; hepatomegaly; steatosis; syndrome X; abnormal alanine aminotransferase levels; polycystic ovarian disease; inflammation; non-alcoholic fatty liver disease; skin disorder; respiratory diseases or disorders including, for example, sinusitis, asthma, bronchitis or combination thereof; pancreatitis; rheumatoid arthritis; cystic fibrosis; pre-menstrual syndrome; cancer; neoplasia; malignancy; metastases; tumors (benign or malignant); hepatomas; neurological diseases; psychiatric disorders; multiple sclerosis; viral diseases/infections or any combination these diseases, disorders, conditions and/or syndromes thereof; the disease or condition related to serumjevels of triglyceride, LDL5 HDL, VLDL, total cholesterol.
In another embodiment, there is provided a method for preventing, ameliorating or treating a disease or condition selected from obesity or related diseases, conditions; diabetes (including Type I and Type II diabetes); diabetic complications; glucose tolerance; hyperinsulinemia; insulin sensitivity or resistance; metabolic syndromes; cardiovascular diseases including, for example, atherosclerosis, lipidemia, dyslipidemia, elevated blood pressure, microalbuminemia, hyperuricaemia, hypercholesterolemia, hyperlipidemias, hypertriglyceridemias, arteriosclerosis or combination thereof; respiratory diseases or disorders including, for example, sinusitis, asthma, bronchitis or combination thereof; or any combination these diseases, disorders, conditions and/or syndromes thereof; the disease or condition related to serum levels of triglyceride, LDL, HDL, VLDL, total cholesterol. In another embodiment, there is provided a method for preventing, ameliorating or treating a disease or condition selected from obesity or related diseases, conditions; Type II diabetes; atherosclerosis, hypertension; lipidemia, dyslipidemia, microalbuminemia, hyperuricaemia, hypercholesterolemia, hyperlipidemias, hypertriglyceridemias, or combination thereof. In another embodiment, there is provided a method for preventing, ameliorating or treating a disease or condition related to serum levels of triglyceride, LDL, HDL, VLDL, total cholesterol. In yet another embodiment there is provided a method for preventing, ameliorating or treating a disease or condition selected from obesity or complication thereof, type II diabetes or complication thereof; cardiovascular diseases or complication thereof, or a combination of these.
General Methods of Preparation
The compounds described herein, including compounds of general formula (I), specific examples, are prepared using techniques known to one of ordinary skill in the art. The compounds described herein are prepared through the reaction sequences as depicted in schemes 1 to 3. All possible stereoisomers are also envisioned within the scope of this invention.
The starting materials for the below reaction schemes are commercially available or can be prepared according to methods known to one skilled in the art or by methods disclosed herein. In general, the compounds according to the present invention may be prepared through the reaction schemes as follows, wherein all symbols are as defined above.
Scheme 1
Figure imgf000021_0001
Scheme 1 depicts a method for preparing the compounds described by general formula (I) wherein all symbols are as defined above. In this scheme, compound of formula (A) is converted to a compound of formula (B) wherein X is halogen, for example, by reacting with molecular halogen or with a halo substituted succinimide in a halogenated solvent or acetonitrile, THF, diethyl ether, acetic acid or the like known in the art of organic synthesis. Compound of formula (B) is converted to a compound of formula (C) by reacting with thiourea (J Chem. Soc, Perkin Trans 1, (1982), 159-164) known in the art of organic synthesis. Compound of formula (C) is converted to a compound of formula (D) by reacting under Sandmeyer reaction conditions with an alkali nitrite in an aqueous acid in the presence of an alkali halide known in the art of organic synthesis. Compound of formula (D) is converted to a compound of formula (E) by reacting with an aqueous alkali under standard ester hydrolysis conditions known in the art of organic synthesis. Compound of formula (E) is converted to a compound of formula (F) by reacting with an appropriately substituted amine under standard amidation conditions employing a coupling reagent such as EDCI.HC1 (l-ethyl-3-(3-dimethylaminopropyl) carbodiimide) hydrochloride) or BOP (benzotriazol-1- yloxytris(dimethylamino)-phosphonium hexafluorophosphate) in the presence of a base such as triethylamine or diisopropylethylamine with or without a catalyst such as DMAP (Dimethylaminopyridine) as known in the art of organic synthesis. Compound of formula (F) is converted to a compound of formula (I) by reacting with an appropriately substituted acetylene under Sonogashira reaction conditions using a base such as triethylamine, diisopropylethylamine or the like or tetra-π-butylammonium fluoride with or without a solvent like DMSO (Dimethyl sulfoxide) in the presence of a copper catalyst such as copper iodide and a palladium catalyst such as (tetrakistriphenylphosphine)palladium(O), in the temperature range of room temperature to 100 0C. Compound of formula (I) (when R3 is O- C(O)-R') can be hydrolyzed to get hydroxyl compound of formula (I) under general ester hydrolysis conditions known in the art.
Substituted acetylene compounds can be prepared as per Scheme 2:
Scheme 2
Figure imgf000022_0001
(G) (H) (J)
Compound of formula (G) is converted to a compound of formula (Ff) by reacting with a silyl acetylene under Sonogashira reaction conditions using a base such as triethylamine, diisopropylethylamine etc., in a solvent such as DMSO in the presence of copper iodide and a palladium catalyst such as (tetrakistriphenylphosphine)palladium(O), in the temperature range of room temperature to 100 0C. Compound of formula (H) is further converted to a compound of formula (J) by reacting with tetra~«-butylammonium fluoride in the presence of a solvent such as dichloromethane in the temperature range of 0 to 80 0C.
Alternately, the compounds of formula (I) can also be prepared as per the following general scheme 3.
Scheme 3
Figure imgf000023_0001
Compound of formula (K) is converted to compound of formula (L) by reacting with the silyl acetylene under Sonogashira reaction conditions using a base such as triethylamine, diisopropylethylamine or the like with a solvent such as DMSO in the presence of a copper catalyst (eg., copper iodide) and a palladium catalyst (eg.,(tetrakistriphenylphosphine) palladium(O)), in the temperature range of room temperature to 100 0C. Compound of formula (L) is converted to a compound of formula (M) by reacting with tetra-rø- butylammonium fluoride in the presence of a solvent such as dichloromethane in the temperature range of 0 to 80 0C. Compound of formula (M) is converted to formula (I) by reacting with an appropriately substituted aryl halide under Sonogashira reaction conditions. Compound of formula (I) (when R3 is O-C(O)-R') can be converted to a hydroxyl compound of formula (I) under general ester hydrolysis conditions known in the art.
EXPERIMENTAL
Intermediates Intermediate 1: 2-Iodo-4-methyl-l,3-thiazole-5-carboxylic acid:
Figure imgf000023_0002
Prepared as per the procedure described inJ. Chem. Soc. Perkin Trans. -1, (1982), 159-164. Stepl: Ethyl 2-amino-4-methyl-l,3-thiazole-5-carboxylate:
To a solution of ethyl 2-chloro acetoacetate (10 g, 60.75 mmoles) in ethanol (50 rnL) was added thiourea (1 eq) and refluxed the reaction mixture for 4 h. The reaction mixture was cooled, and then added crushed ice, .neutralized with ammonia. The precipitate was then filtered and dried under vacuum to give 11.5 g of the desired product. 1H NMR (DMSO-d6) δ 7.69 (s, 2H), 4.16-4.09 (q, J= 6.6 Hz, 2H), 2.36 (s, 3H), 1.22 (t, J= 6.9 Hz, 3H). MS (m/z): 185.40 (M-H)+.
Step 2: Ethyl 2-iodo-4-methyl-l,3-thiazole-5-carboxylate:
A slurry of ethyl 2-amino-4-methyl-l,3-thiazole-5-carboxylate (11.4 g, 61.21 mmoles) and a solution of NaI (2 eq) in water (80 mL) was added to a stirred solution at -8 0C of CuSO4 (1.5 eq) and H2SO4 (175 mL) in water (425 mL). A solution OfNaNO2 (1.9 eq) in water (25 mL) was added beneath the surface of the mixture for 30 min and the mixture was allowed to warm to 8 0C for 1 h. The reaction mixture was then extracted with diethyl ether and the organic layer was then dried over Na2SO4 and concentrated to get 6.5 g of the desired product. 1H NMR (CDCl3) δ 4.28-4.21 (q, J= 6.9 Hz, 2H)5 2.63 (s, 3H), 1.27 (t, J= 6.9 Hz, 3H).
Step 3: 2-Iodo-4-methyl-l,3-thiazole-5-carboxylic acid:
A mixture of ethyl 2-iodo-4-methyl-l,3-thiazole-5-carboxylate (6.5 g, 21.87 mmoles) and KOH (2.4 eq) in 15 % aqueous ethanol (60 mL) was refluxed for 2 h. Ethanol was evaporated from the reaction mixture and washed with diethyl ether. The aqueous layer was then acidified with 2 N HCl. The precipitated product was then filtered and dried under vacuum to get 5.7 g of desired product. 1H NMR (DMSO-d6) δ 13.17 (br s, IH), 2.60 (s, 3H). MS (m/z): 267.83 (M-H)+.
Intermediate 2: N-(4-Fluorobenzyl)-2-iodo-4-methyl-l,3-thiazole-5-carboxamide:
Figure imgf000024_0001
To a solution of intermediate 1 (0.5g, 1.86 mmoles) in CH2Cl2 (10 mL) at room temperature was added EDCI. HCl (1.5 eq) followed by N, N'-diisopropylethylamine (3 eq), HOBT (hydroxybenzotriazole) (1 eq) and 4-fluoro benzylamine (1 eq) and stirred the reaction mixture at room temperature for 16 h. The reaction mixture was then diluted with dichloromethane (30 mL) and washed with water (20 mL) followed by brine, dried over Na2SO4 and concentrated. The crude was then purified by column chromatography to get 0.4 g of the desired product. 1H NMR (DMSOd6) δ 8.78 (br, s, IH), 7.35-7.30 (m, 2H), 7.14 (t, J = 8.7 Hz5 2H), 4.36 (d, J= 5.7 Hz, 2H), 2.54 (s, 3H).
Intermediate-3 : 2-Iodo-4-methyl-iV-(3 -phenylpropyl)- 1 ,3 -thiazole- 5 -carboxamide :
Figure imgf000025_0001
The title compound was prepared by following the similar procedure as described in intermediate 2 by using intermediate 1 (0.4 g, 1.49 mmoles) and 3-phenylpropan-l-amine (1 eq) to get 0.28 g of the required product. 1H NMR (DMSO-d6) δ 7.30-7.10 (m, 5H); 5.61 (br s, IH); 3.46-3.40 (q, J= 6.0 Hz, 2H); 2.70 (t, J= 7.5 Hz, 2H); 2.62(s, 3H); 1.94 (p, J - 7.5 Hz, 2H).
Intermediate- 4: 2-Iodo-4-methyl-iV-[(»S}-(-)(l-phenylethyl)]-l,3-thiazole-5- carboxamide:
Figure imgf000025_0002
The title compound was prepared by following the similar procedure as described in intermediate 2 by using intermediate 1 (0.4 g, 1.49 mmoles) and (£)-(-) 1-phenylethanamine (1 eq) to get 0.26 g of the required product. 1H NMR (CDCl3) δ 7.40-7.25(m, 5H); 5.85 (br d, IH); 5.21(p, J= 7.2 Hz, IH); 2.66 (s, 3H ); 1.57 (br d, 3H).
Intermediate- 5: N-(4-Chlorobenzyl)-2-iodo-4-methyl-l,3-thiazole-5- carboxamide:
Figure imgf000025_0003
The title compound was prepared by following the similar procedure as described in intermediate 2 by using intermediate 1 (0.4 g, 1.49 mmoles) and l-(4- chlorophenyl)methanamme (1 eq) to get 0.32 g of the required product. 1H NMR (DMSOd6) δ 8.80 (t, 3H); 7.38 (d, J= 8.4Hz, 2H); 7.30(d, J= 8.4 Hz, 2H); 4.37(d, 2H, J= 5.7 Hz); 2.55 (s, 3H).
Intermediate-6: N-[l-(4-Fluorophenyl)etliyl]-2-iodo-4-methyl-l,3-thiazole-5 carboxamide:
Figure imgf000026_0001
The title compound was prepared by following the similar procedure as described in intermediate 2 by using intermediate 1 (0.4 g, 1.49 mmoles) and l-(4- fluorophenyl)ethanamine (1 eq) to get 0.25 g of the required product. 1H NMR (DMSO-d6) δ 8.67 (d, IH, J= 8.1 Hz); 7.39-7.36 (m, 2H); 7.13 (t, 2H, J= 17.4 Hz); 5.06-5.01(m, IH); 2.50 (s, 3H); 1.42(s, 3H).
Intermediate- 7: iV-(2,4-DifluoiObenzyl)-2-iodo-4-methyl-l,3-thiazole-5- carboxamide:
Figure imgf000026_0002
The title compound was prepared by following the similar procedure as described in intermediate 2 by using intermediate 1 (0.4 g, 1.49 mmoles) and l-(2,4- difluorophenyl)methanamine (1 eq) to get 0.31 g of the required product. 1H NMR (DMSO- d6) δ 8.77 (t, IH); 7.37 (q, IH, J = 7.2 Hz); 7.26 (t, IH); 7.04 (t, IH); 4.38 (d, 2H, J = 5.4 Hz); 2.53 (s, 3H).
Intermediate- 8: N-[2-(4-Fluorophenyl)ethyl]-2-iodo-4-methyl-l,3-thiazole-5- carboxamide:
Figure imgf000026_0003
The title compound was prepared by following the similar procedure as described in intermediate 2 by using intermediate 1 (0.4 g, 1.49 mmoles) and 2-(4- fluorophenyl)ethanamine (1 eq) to get 0.30 g of the required product. 1H NMR (DMSO-d6) δ 8.27 (br s, IH); 7.06-7.11 (m, 2H); 7.24-7.20 (m, 2H); 3.39(m, 2H); 2.78 (t, 2H, J= 13.5 Hz); 2.45 (s,3H). Intermediate- 9: iV-(3-Chlorobenzyl)-2-iodo-4-methyl-l ,3-thiazole-5-carboxamide:
Figure imgf000027_0001
The title compound was prepared by following the similar procedure as described in intermediate 2 by using intermediate 1 (0.4 g, 1.49 mmoles) and l-(3-chlorophenyl) methanamine(l eq) to get 0.28 g of the required product. 1H NMR (DMSOd6) δ 8.08 (m, IH); 7.35-7.25 (m, 4H); 4.36 (d, 2H, J= 6.0 Hz); 2.55 (s, 3H).
Intermediate- 10: 2-Iodo-iV-(4-methoxybenzyI)-4-methyl-l ,3-thiazole-5-carboxamide:
Figure imgf000027_0002
The title compound was prepared by following the similar procedure as described in intermediate 2 by using intermediate 1 (0.4 g, 1.49 mmoles) and l-(4-methoxyphenyl) methanamine (1 eq) to get 0.32 g of the required product. 1H NMR (DMSOd6) δ 8.71 (m, IH); 7.19 (d, 2H, J= 8.1 Hz); 6.86 (d, 2H, J= 9.0 Hz); 4.30 (d, 2H, J= 5.7 Hz); 3.71 (s, 3H); 2.53(s, 3H).
Intermediate- 11 : 2-Iodo-4-methyl-iV-[4-(trifluoromethyl)benzyl]-l,3-thiazole-5-carbox- amide:
Figure imgf000027_0003
The title compound was prepared by following the similar procedure as described in intermediate 2 by using intermediate 1 (0.4 g, 1.49 mmoles) and l-[4-(trifluoromethyl) ρhenyl]methanamine (1 eq) to get 0.27 g of the required product.1H NMR (DMSOd6) δ 7.60 (d, 2H, J= 7.8 Hz); 7.42 (d, 2H, J- 7.8 Hz); 6.10 (br s, IH); 4.63 (d, 2H, J= 5.7 Hz); 2.70 (s, 3H).
Intermediate- 12 : N-(2,6-Difiuorobenzyl)-2-iodo-4-methyl- 1 ,3 -thiazole-5 -carboxamide:
Figure imgf000027_0004
The title compound was prepared by following the similar procedure as described in intermediate 2 by using intermediate 1 (0.4 g, 1.49 mmoles) and l-(2,6-difluorophenyl) methanamine (1 eq) to get 0.29 g of the required product. 1H NMR (DMSOd6) δ 8.73 (m, IH); 7.40-7.33 (m, IH); 7.07 (t, 2H5 J= 15.6 Hz); 4.43 (d, 2H, J= 5.4 Hz); 2.49 (s, 3H).
Intermediate- 13 : 7V-(2-Chlorobenzyl)-2-iodo-4-methyl-l ,3-thiazole-5-carboxamide:
Figure imgf000028_0001
The title compound was prepared by following the similar procedure as described in intermediate 2, using intermediate 1 (0.4 g, 1.49 mmoles) and 2-Chlorobenzylamine (1 eq) to get 0.30 g of the required product. 1H NMR (DMSOd6) δ 8.80 (br, s, IH)5 7.44 (d, J = 7.8 Hz, IH), 7.35-7.20 (m, 3H), 4.45 (d, J= 5.1 Hz, 2H)5 2.56 (s, 3H).
Intermediate- 14: 2-Iodo-4-methyl-iV-[(if)-(+)-(l-phenylethyl)]-l,3-thiazole-5- carboxamide:
Figure imgf000028_0002
The title compound was prepared by following the similar procedure as described in intermediate 2 by using intermediate 1 (0.4 g, 1.49 mmoles) and (i?)-(+)l-phenylethanamine (1 eq) to get 0.30 g of the required product. 1H NMR (CDCl3) δ 7.38-7.25(m, 5H); 5.90-5.82 (m, IH); 5.21 (p, J= 7.2 Hz, IH); 2.66 (s, 3H); 1.59 (d, J= 3.3 Hz, 3H); MS (m/z): 373.04 (M)+.
Intermediate- 15: 4-(Trimethylsilanylethynyl)-phenylacetate:
Figure imgf000028_0003
To a solution of 4-acetoxy iodobenzene (6.0 g, 22.89 mmoles) in DMSO (25 mL) was added trimethylsilyl acetylene (1.1 eq) followed by triethylamine (3 eq), CuI (0.05 eq) and tetrakis (triρhenylphosphine)palladium(O) (0.03 eq) and the reaction mixture was stirred at room temperature for 6 h. The reaction mixture was then diluted with water and extracted with ethyl acetate. The organic layer was then dried over Na2SO4, concentrated and purified by column chromatography to get 4.5 g of the desired product. 1H NMR (DMSOd6) δ 7.48 (d, J - 8.7 Hz5 2H), 7.12 (d, J= 8.4 Hz, 2H), 2.26 (s, 3H), 0.23 (s, 9H).
Intermediate- 16: 4-(l-Ethynyl)phenylacetate:
Figure imgf000029_0001
To a solution of 4-(trimethylsilanylethynyl)-phenylacetate (4.4 g, 18.93 mmoles) in dichloromethane (50 mL) at 0 0C was added tetra-rø-butylammonium fluoride (0.5 eq) and stirred the reaction mixture at room temperature for 1 h. The reaction mixture was then diluted with dichloromethane, washed with water, dried over Na2SO4, concentrated and purified by column chromatography to get 1.9 g of the desired product. 1H NMR (CDCl3) δ 7.47 (d, J= 7.8 Hz, 2H), 7.03 (d, J= 8.1 Hz, 2H), 3.05 (s, IH), 2.29 (s, 3H).
Intermediate- 17: 3-(Trimethylsilanylethynyl)-phenylacetate:
Figure imgf000029_0002
To a solution of 3-acetoxy iodobenzene (6.0 g, 22.89 mmoles) in DMSO (25 mL) was added trimethylsilyl acetylene (1.1 eq) followed by triethylamine (3 eq), CuI (0.05 eq) and tetrakis (triphenylphosphine) palladium(O) (0.03 eq) and the reaction' mixture was stirred at room temperature for 6 h. The reaction mixture was then diluted with water and extracted with ethyl acetate. The organic layer was then dried over Na2SO4, concentrated and purified by column chromatography to get 4.3 g of the desired product. 1H NMR (CDCl3) δ 7.30-7.25 (m, 2H), 7.18 (s, IH), 7.05-6.95 (m, IH), 2.28 (s, 3H), 0.24 (s, 9H).
Intermediate- 18: 3-(l-Ethynyl)phenylacetate:
Figure imgf000029_0003
To a solution of 3-(trimethylsilanylethynyl)-phenylacetate (4.0 g, 17.21 mmoles) in dichloromethane (50 mL) at 0 0C was added tetra-n-butylammonium fluoride (0.5 eq) and stirred the reaction mixture at room temperature for 1 h. The reaction mixture was then diluted dichloromethane, washed with water, dried over Na2SO4, concentrated and purified by column chromatography to get 1.5 g of the desired product. 1H NMR (CDCl3) δ 7.35-7.25 (m, 2H), 7.19 (s, IH), 7.10-7.00 (m, IH), 3.08 (s, IH), 2.29 (s, 3H). Intermediate 19: Ethyl 2-bromo-4,4,4-trifluoro-3-oxobutanoate:
O O
F3U J O
Br
Solution of ethyl 4,4,4-trifluoro-3-oxobutanoate (5g, 27.16 mmoles) in CCl4 (50ml) was chilled at 10-15 0C and added bromine solution (0.97 eq). Stir at room temperature for 1 h. Added chloroform and reaction mass washed with DM water (100ml) followed by sodium bisulphite solution (50ml). Collect organic layer dried over sodium sulphate and excess of solvent distilled out and concentrated to get 4.48 g of desired product. 1H NMR (CDCl3) δ 4.33 (m, IH); 1.30 ( m,3H).
Intermediate 20: Ethyl 2-amino-4-(trifluoromethyl)-l,3-thiazole-5-carboxylate:
Figure imgf000030_0001
To a solution of ethyl 2-bromo-4,4,4-trifluoro-3-oxobutanoate (4.48 g, 17.03 mmoles) in ethanol (50 ml) added thiourea (2 eq ) and refluxed at 85 0C for 24 h. Then ethanol was distilled out, added chilled water, adjusted pH 10-14 with Ammonia solution. The obtained precipitate was then filtered and dried in oven at 40-45 0C to give 1.7 g of desired product. 1H NMR (CDCl3) δ 8.22 (s, 2H); 4.21 (q, 2H, J= 13.8Hz); 1.23 ( t, 3H, J =13. S Hz ). MS (m/z): 239.19 (M-H)-.
Intermediate 21: Ethyl 2-iodo-4-(trifluoromethyl)-l,3-thiazole-5-carboxylate:
Figure imgf000030_0002
To solution of Para toluene sulphonic acid (2.3 g, 13.35 mmoles) in acetonitrile (20 ml) was slowly added powdered ethyl 2-ammo-4-(trifluoromethyl)-l,3-thiazole-5-carboxylate(l g, 4.16 mmoles). Heat the reaction mixture at 40-50 0C for 30mins. The reaction mixture was then cooled to 10-15 0C. Then solution OfNaNO2 (2 eq) added and KI (2.5 eq) was added to above reaction mixture and maintained at room temperature for 1 h. Then reaction mass was quenched in ice cold water (30ml). The reaction mixture was extracted with dichloromethane (100ml) and further extracted with dichloromethane. Washed the total organic layers with 5% sodium bisulphate solution (100ml), dried over Na2SO4 and concentrated. The crude was then purified by column chromatography to get 0.755 g of the desired product. 1H NMR (CDCl3) δ 4.30 (q, 2H, J= 14.7 Hz); 1.28 ( t, 3H, 7=13.5 Hz); MS (m/z): 351.91 (M+H)+
Intermediate 22: 2-Iodo-4-(trifluoromethyl)-l,3-thiazole-5-carboxylic acid:
Figure imgf000031_0001
To a solution of 2-iodo-4-(trifluoromethyl)-l,3-thiazole-5-carboxylate (3.4 g, 9.68 mmoles) in THF at was added solution NaOH (2 eq) and stir at room temperature. Distilled out the solvent completely and DM water (2 ml) was added and adjusted pH to 1 with IN HCl. The obtained precipitate was filtered, washed with DM water to get 2.4 g of desired product.
Intermediate 23 : 2-Iodo-iV-(3-phenylpropyl)-4-(trifluoromethyl)- 1 ,3-thiazole-5-carboxamide:
Figure imgf000031_0002
To a solution of 2-Iodo-4-(trifluoromethyl)-l,3-thiazole-5-carboxylic acid ( 0.211 g, 0.65 mmoles) in dichloro ethane was added EDCI.HC1 (1 eq), HOBT (1 eq) and DIPEA (N,N- diisopropylethylamine) ( 0.230 g) followed by phenylpropylamine ( 0.108 g) and stirred at room temperature for 3 h. To above reaction mixture was added ethyl acetate and DM water (5 ml) and extracted into organic layer. Further aqueous layer was extracted with ethyl acetate (2 x 10ml). Total organic, layers dried over Na2SO4 and concentrated. The obtained crude product was purified through column chromatography to get 0.191 g of desired product. 1H NMR (DMSO-de) δ 8.95 (br, s, IH), 7..27 (t, J = 14.7 Hz, 3H), 7.18 (d, J= 7.8 Hz, 2H), 3.19-3.21 (q, J= 6.0 Hz, 2H), 2.36 (t, J= 15.3 Hz, 2H ); 1.75 (t, J= 14.1 Hz, 2H ). MS (m/z); 440.92 (M+H)+.
Intermediate 24: 2-iodo-iV-(2-Phenylethyl)-4-(trifluoromethyl)-l,3-thiazole-5-carboxamide:
Figure imgf000031_0003
The title compound was prepared by following the similar procedure as described in intermediate 23 by using intermediate 22 (0.35 g, 1.08 mmoles) and phenylethylamine (1 eq) instead of phenylpropylamine to get 0.171g of the desired product. 1H NMR (DMSOd6) δ 8.98 (br, s, IH), 1.21 (t, J= 6.6 Hz5 3H), 7.20 (d, J = 7.2 Hz, 2H), 3.43(d, J = 6.6 Hz, 2H), 2.76 (t, J= 7.2 Hz, 2H ).
Intermediate 25 : 2-Iodo-iV-(4-fluorobenzyl)-4-(trifluoromethyl)- 1 ,3-thiazole-5-carboxamide:
Figure imgf000032_0001
The title compound was prepared by following the similar procedure as described in intermediate 23 by using intermediate 22 (0.35 g, 1.08 mmoles) and 4-fluorobenzylamine (1 eq) instead of phenylpropylamine to get 0.21 g of the desired product. 1H NMR (DMSOd6) δ 9.42 (br, s, IH), 7.40-7.30 (m, 2H), 7.20-7.10 (m, 2H), 4.39 (d, J= 6.0 Hz, 2H).
Intermediate 26: 2-Iodo-N-(4-trifluoromethyl benzyl)-4-(trifluoromethyl)-l,3-thiazole-5- carboxamide:
Figure imgf000032_0002
The title compound was prepared by following the similar procedure as described in intermediate 23 by using intermediate 22 (0.35 g, 1.08 mmoles) and 4-trifluoromethylbenzyl amine (1 eq) instead of phenylpropylamine to get 0.14 g of the desired product. 1H NMR (DMSOd6) δ 9.51 (br, s, IH), 7.70 (d, J= 8.1 Hz, 2H), 7.48 (d, J= 7.8 Hz, 2H), 4.50 (d, J= 5.7 Hz, 2H). MS (m/z): 478.86 (M-H)".
Intermediate 27: 2-Iodo-iV-(4-methoxy benzyl)-4-(trifluoromethyl)-l,3-thiazole-5- carbox amide:
Figure imgf000032_0003
The title compound was prepared by following the similar procedure as described in intermediate 23 by using intermediate 22 (0.35 g, 1.08 mmoles) and 4-methoxybenzylamine (1 eq) instead of phenylpropylamine to get 0.18 g of the desired product. 1H NMR (DMSO- d6) δ 9.34 (br, s, IH), 7.19 (d, J= 9.0 Hz, 2H), 6.88 (d, J= 9.0 Hz5 2H), 4.33 (d, J = 6.0 Hz, 2H), 3.72 (s, 3H).
Intermediate 28: 2-Iodo-iV-benzyl-4-(trifluoromethyl)-l,3-thiazole-5-carboxamide:
Figure imgf000033_0001
The title compound was prepared by following the similar procedure as described in intermediate 23 by using intermediate 22 (0.35 g, 1.08 mmoles) and benzylamine (1 eq) instead of phenylpropylamine to get 0.19 g of the desired product. 1H NMR (DMS O-d6) δ 9.42 (br, s, IH), 7.35-7.25 (m, 5H), 4.41 (d, J= 6.0 Hz, 2H).
Intermediate 29: 4-Cyclopropyl-2-[(4-hydroxyphenyl)ethynyl]-l,3-thiazole-5-carboxylic acid
Figure imgf000033_0002
Step 1 : Ethyl 2-bromo-3-cyclopropyl-3-oxopropanoate:
To a solution of ethyl 3-cyclopropyl-3-oxopropanoate (400 mg, 2.56 mmoles) in CCl4 (10 ml) was added aq. Br2 (0.99 eq) and the reaction mixture was stirred at room temperature for 1 h. Then the reaction mixture was quenched in water and the organic layer was washed with sodium bisulphate and then washed with water and concentrated to give 500 mg of desired product. 1H NMR (CDCl3) δ 5.61 (m, IH); 4.21 (q, 2H5 J = 28.2 Hz)5 2.51 (m, IH); 1.41(t, 3H, J= 16.5 Hz); 1.31(m, 2H); 0.95 (m, 2H).
Step 2: Ethyl 2-amino-4-cyclopropyl-l,3-thiazole-5-carboxyl ate:
To a solution of thiourea (500 mg, 6.57 mmoles) in ethanol (10 ml) was added 2-bromoethyl cyclopropyl acetate (1.16 eq) and heated to 80 0C. Evaporate the ethanol then water was added and extracted with ethyl acetate, and purified through column to get 500 mg of desired product. 1H NMR (CDCl3) 8 7.69 (s br, 2H); 4.15 (q, 2H5 J= 21.6 Hz)5 2.87 (m, IH); 1.22 (t, 3H, J= 14.1 Hz); 0.88 (m, 4H). Step 3: Ethyl -4-cyclopropyl-2-iodo l,3-thiazole-5-carboxylate:
To a solution of ethyl 2-amino-4-cyclopropyl-l,3-thiazole-5-carboxylate (0.5 g, 2.35 mmoles) in acetonitrile (10 ml) was added PTSA (p-toluenesulfonicacid) (4.0 eq) and stirred for 30 min. Allow the reaction mixture at 0 0C and was added KI (2.5 eq) and NaNO2 (2.0 eq) and stirred for 30 min at 0 0C. Then raise the temperature to 90 0C for 15 min and quenched in water and then extracted with ethyl acetate. Organic layer was concentrated and purified through column to get 400 mg of desired product. 1H NMR (DMSO-d6) δ 4.27 (q, 2H, J = 13.8 Hz); 2.91 (m, IH); 1.26 (t, 3H, J= 13.8 Hz); 1.09 (m, 2H); 0.97 (m,2H).
Step 4: Ethyl 2-{[4-(acetyloxy) phenyl] ethynyl}-4-cyclopropyl-l, 3-thiazole-5-carboxylate:
To a solution of ethyl-4-cycloρropyl-2-iodo l,3-thiazole-5-carboxylate (0.45 g, 1.39 mmoles) in DMSO (5 ml) and triethylamine (2ml) was added 4-acetoxy phenyl acetylene (1 eq) and Pd(PPh3)Cl2 (0.03 eq) and stirred for 2 h at room temperature. Then quenched in water and extracted in ethyl acetate and concentrated to get 450mg of desired product. 1H NMR (DMSO-d6) δ 7.73 (d, 2H, J= 8.1 Hz); 7.25(d, 2H, J = 8.1 Hz); 4.32 (q, 2H, J = 21.0 Hz); 2.98 (m, IH); 2.87(s, 3H); 1.30(t, 3H, J= 13.8 Hz); 1.29 (m,2H); 1.04 (m,2H).
Step 5: 4-Cyclopropyl-2-[(4-hydroxyphenyl)ethynyl]-l,3-thiazole-5-carboxylic acid:
To a solution of ethyl 2-{[4-(acetyloxy) phenyl]ethynyl}-4-cyclopropyl-l,3-thiazole-5- carboxylate (400 mg, 1.12 mmoles) in ethanol was added sodium hydroxide (3.3 eq) and stirred at room temperature. Then quenched in water and acidified with acetic acid to get 270 mg of desired product. 1H NMR (DMSO-d6) δ 13.52 (s br, IH); 10.23 (s,lH); 7.48 (d, 2H, J= 8.4 Hz); 6.82 (d, 2H, J= 8.1 Hz); 2.98 (m, IH); 1.08 (m, 2H); 0.99 (m,2H).
Intermediate 30: jV-[2-(4-Fluorophenoxy)ethyl]-2-iodo-4-methyl-l ,3~thiazole-5-carboxamide:
Figure imgf000034_0001
Step 1- fer/-Butyl (2-hydroxyethyl)carbamate:
To a solution of 2-aminoethanol (1 g, 16.32 mmoles) in dichloromethane (10 ml) was added triethylamine (3 eq) and stirred for 10 mins. Then BOC anhydride (1.2 eq) was added to the reaction mixture and stirred for 2 h at room temperature. Then the reaction mixture was quenched in ice cold water and extracted with dichloromethane. The organic layer was washed with water and concentrated to get desired product. 1H NMR (CDCl3) δ 7.25 (s, IH), 3.69 (t, 2H5 J= 12.6 Hz), 3.48 (s,lH); 3.28 (m, 2H).
Step 2: tert-Bxxty\ [2-(4-fluorophenoxy)ethyl]carbamate :
Under nitrogen atmosphere to a solution of 4-fluoro phenol (0.5g, 4.46 mmoles) and tert- butyl (2-hydroxyethyl) carbamate (1 eq) in tetrahydrofuran (2.5 ml) was added triphenyl phosphine (1.5 eq) and diethylazodicarboxylate (1.2 eq) drop wise and refluxed the reaction mixture for 3 h. Then the reaction mixture was quenched in ice cold water and extracted with ethyl acetate. The organic layer was washed with water and concentrated to get desired product. The crude product was further purified by column chromatography to get 275 mg of pure desired product. 1H NMR (CDCl3) δ 7.24 (s, IH), 6.92 (m, 2H); 6.49 (m, 2H); 3.96 (t, 2H, J= 9.6 Hz), 3.50 (m,2H); 1.45 (s, 9H)
Step 3 : Hydrochloride salt of 2-(4-fluorophenoxy)ethanamine:
To tert-butyl [2-(4-fluorophenoxy)ethyl]carbamate added ethyl acetate HCl and stirred at room temperature for 15 mins. Then ethyl acetate was evaporated and the product was dried and used for next step.
Step 4: N-[2-(4-Fluorophenoxy)ethyl]-2-iodo-4-methyl-l,3-thiazole-5-carboxamide:
To the solution of intermediate 1 (300 mg, 1.11 mmoles) in dichloromethane was added DIPEA (2 eq.), HOBT (1 eq), and EDCI (1.5 eq) followed by the addition of product of step 1 dissolved in dichloromethane and DIPEA (1 eq). The reaction mixture was then stirred at room temperature for 6 h. Then quenched the reaction mixture with ice cold water and extracted with dichloromethane. Then the organic layer was washed with brine and water and dried over Na2SO4 and concentrated to get crude product. The crude material was purified through column chromatography to get 200 mg of the desired product. 1H NMR (CDCl3) δ 8.45 (m, IH); 7.09 (m, 2H); 6.95 (m, 2H); 4.04 (t, 2H); 3.53 (d, 2H, 7=5.1 Hz); 2.52 (s, 3H).
Intermediate 31 : 2~Iodo-4-methyl-N-(2-phenoxyethyl)-l,3-thiazole-5-carboxamide:
Figure imgf000035_0001
Step 1: tert-butyl (2-phenoxyethyl)carbamate:
By following the similar procedure as described in step-2 of intermediate-30 by using phenol (0.5 g, 5.31 mmoles) and tert-butyl (2-hydroxyethyl) carbamate (step 1, intermediate 30, 1 eq) to get 300 mg of the desired product. 1H NMR (CDCl3) δ 7.27 (m, 3H); 6.97 (m, IH); 6.87 (m, 2H); 4.02 (t, 2H, J= 9.3 Hz); 3.52 (m, 2H); 1.45 (s, 3H)
Step 2: Hydrochloride salt of 2-phenoxyethanamine:
To tert-butyl (2-phenoxyethyl)carbamate added ethyl acetate HCl and stirred at room temperature for 15 mins. Then ethyl acetate was evaporated and the product was dried and used for next step. 1H NMR (CDCl3) δ 8.16 (m, 2H); 7.30 (t, 2H, J= 15.3 Hz); 6.96 (d, 3H5 J = 8.4 Hz); 4.16 (t, 2H, J= 9.3 Hz); 3.19 (m, 2H)
Step 3 : 2-Iodo-4-methyl-Λf-(2-phenoxyethyl)-l,3-thiazole-5-carboxamide:
To the solution of intermediate 1 (300 mg, 1.11 mmoles) in dichloromethane was added DIPEA (3 eq) and BOP reagent (1 eq). Then the solution of hydrochloride salt of 2- phenoxyethanamine (1 eq) in dichloromethane and DIPEA (1 eq) was added to the above reaction mixture and maintained at room temperature for 3 h. The reaction mixture was quenched with ice cold water and extracted with dichloromethane. Then the organic layer was washed with brine and water and dried over anhydrous sodium sulphate and concentrated to get crude product. The crude material was purified by column chromatography to get 175 mg of the desired product. 1H NMR (CDCl3): δ 8.45 (br s, IH); 7.26 (t, 2H, J = 15.6 Hz); 6.90 (m, 3H); 4.06 (t, 2H, J= 11.1 Hz); 3.56 (m, 2H); 2.53 (s, 3H).
Intermediate 32: i\T-(2/l-Dichlorobenzyl)-2-iodo-4-methyl-l ,3-thiazole-5-carboxamide:
Figure imgf000036_0001
By following the similar procedure as described in intermediate 2 by using intermediate 1 (0.4 g, 1.48 mmoles) and l-(2,4-dichIorophenyl) methanamine (1 eq) to get 0.3 g of the required product. 1H NMR (CDCl3) δ 8.80 (t, IH); 7.60 (s, IH); 7.40 (d, IH, J= 8.4 Hz); 7.34 (d, IH, J= 8.1 Hz); 4.42 (d, 2H, J= 5.4 Hz); 2.55(s, 3H).
Examples Example 1 iV-5-Benzyl-2-[2-(3-hydroxyphenyl)- 1 -ethynyl]-4-methyl- 1 ,3-thiazole-5-carboxamide:
Figure imgf000036_0002
Step 1 : iV-5-Benzyl-2-biOmo-4-methyl-l,3-thiazole-5-carboxamide:
To a solution of 2-iodo-4-methyl-l,3-thiazole-5-carboxylic acid (intermediate 1, 0.5g, 1.85 mmoles) in DMF (3 niL) at room temperature was added BOP reagent (1 eq) and stirred the reaction mixture at room temperature for 30 min. To the above reaction mixture added N, If- diisopropylethylamine (2 eq) followed by benzylamine (1 eq) and maintained at room temperature for 3 h. The reaction mixture was then diluted with water (10 mL) and extracted with ethyl acetate (2 x 25 mL). The organic layer was then washed with water (3 x 20 mL) followed by brine, dried over Na2SO4 and concentrated. The crude was then purified by column chromatography to get 350 mg of the desired product. 1H NMR (DMSO-d6) δ 8.83 (br, t, IH), 7.35-7.25 (m, 5H), 4.39 (d, J= 6.0 Hz, 2H), 2.54 (s, 3H).
Step 2: To iV-5-Benzyl-2-iodo-4-methyl-l,3-thiazole-5-carboxamide (100 mg, 0.28 mmoles) (step 1) was added tetra-«-butyl -ammonium fluoride (3 eq) followed by 3-(l- ethynyl)phenylacetate (1 eq) and stirred the reaction mixture at 80 0C for 3 h. The reaction mixture was then diluted with ethyl acetate and washed with water. The organic layer was then dried over Na2SO4, concentrated and purified by column chromatography to get 45 mg of the desired product. 1H NMR (DMSO-d6) δ 9.88 (s, IH), 8.91 (br t, IH), 7.35-7.20 (m, 6H), 7.06 (d, J= 7.5 Hz, IH), 6.97 (s, IH), 6.91 (d, J = 6.0 Hz, IH), 4.43 (d, J= 6.0 Hz, 2H), 2.58 (s, 3H). MS (m/z): 347.30 (M-H)+.
Example 2 iV-5-Benzyl-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5-carboxamide:
Figure imgf000037_0001
The title compound was prepared by following the similar procedure as described in step 2 of example 1, using the product of step 1 of example 1 (100 mg, 0.28 mmoles) and 4-(l- ethynyl) phenylacetate (1 eq) instead of 3-(l-ethynyl) phenylacetate to get 38 mg of the desired product. 1H NMR (CDCl3) δ 10.21 (s, IH), 8.85 (br t, IH), 7.47 (d, J= 8.4 Hz, 2H), 7.40-7.20 (m, 5H), 6.82 (d, J= 8.1 Hz, 2H), 4.42 (d, J= 5.4 Hz, 2H), 2.57 (s, 3H); MS (m/z); 347.33 (M-H)+.
Example 3 iV-5-(3-Pyridylmethyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5- carboxamide:
Figure imgf000038_0001
Step 1: jV-5-(3-Pyridylmethyl)-2-bromo-4-methyl- 1 ,3-thiazole-5-carboxamide:
By following the similar procedure as described in Step 1 of example 1 , using intermediate 1 (0.5 g, 1.86 mmoles) and 3-(aminomethyl) pyridine (1 eq) instead of benzylamine to get 350 mg of the desired product. 1H NMR (DMSOd6) δ 8.87 (br, t, IH), 8.51 (s, IH), 8.44 (d, J = 3.6 Hz, IH), 7.70 (d, J = 7.8 Hz, IH), 7.39-7.32 (m, IH), 4.42 (d, J = 6.0 Hz, 2H), 2.54 (s, 3H).
Step 2: By following the similar procedure as described in step 2 of example 1 using iV-5-(3- pyridylmemyl)-2-iodo-4-methyl-l53-thiazole-5-carboxamide (100 mg, 0.28 mmoles) and 4- (l-ethynyl)phenylacetate (1 eq) to get 41 mg of the desired product. 1H NMR (DMSO-d6) δ 10.22 (s, IH), 8.90 (br t, IH), 8.53 (s, IH), 8.45 (br S5 IH), 7.73 (d, J= 6.3 Hz, IH), 7.46 (d, J = 8.4 Hz, 2H), 7.37 (br s, IH), 6.82 (d, J- 8.1 Hz, 2H), 4.44 (d, J= 4.8 Hz, 2H), 2.57 (s, 3H). MS (m/z): 350.29 (M+H)+.
Example 4 iV-5-(3-Pyridylmethyl)-2-[2-(3-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5- carboxamide
Figure imgf000038_0002
The title compound was prepared by following the similar procedure as described in step 2 of example 1, using iV5-(3-pyridylmethyl)-2-iodo-4-methyl-l,3-thiazole-5-carboxamide (100 mg, 0.28 mmoles) and 3-(l-ethynyl) phenylacetate to get 32 mg of the desired product. 1H NMR (DMSOd6) δ 10.22 (s, IH), 8.90 (br t, IH), 8.53 (s, IH)5 8.45 (br s, IH)5 7.73 (d, J = 6.3 Hz5 IH)5 7.46 (d, J = 8.4 Hz, 2H), 7.37 (br s, IH), 6.82 (d, J= 8.1 Hz, 2H)5 4.44 (d, J = 4.8 Hz5 2H), 2.57 (s, 3H). MS (m/z): 350.39 (M+H)+.
Example 5 iV-5-(2-Pyridylmethyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5-carbox- amide:
Figure imgf000039_0001
Step 1 : Λr-5-(2-Pyridylmethyl)-2-iodo-4-methyl- 1 ,3-thiazole-5-carboxamide:
To a solution of 2-iodo-4-methyl-l,3-thiazole-5-carboxylic acid (intermediate I5 0.5g, 1.86 mmoles) in dichloromethane (10 niL) at room temperature was added EDCI. HCl (1.5 eq) followed by N, iV'-diisopropylethylamine (3 eq), HOBT (1 eq) and 2-(aminomethyl) pyridine (1 eq) and stirred the reaction mixture at room temperature for 16 h. The reaction mixture was then diluted with CH2Cl2 (30 mL) and washed with water (20 mL) followed by brine, dried over Na2SO4 and concentrated. The crude was then purified by column chromatography to get 400 mg of the desired product. 1H NMR (DMSO-d6) δ 8.82 (br, t, IH), 8.48 (d, J- 3.9 Hz, IH), 7.74 (t, J= 6.0 Hz, IH), 7.30-7.20 (m, 2H)5 4.48 (d, J= 6.0 Hz, 2H), 2.57 (s, 3H).
Step 2: 4-{2-[4-Methyl-5-(2-pyridylmethylcarbamoyl)-l,3-thiazol-2-yl]-l-ethynyl}-phenyl acetate:
Figure imgf000039_0002
To a solution of iV-5-(2-pyridylmethyl)-2-iodo-4-methyl-l,3-thiazole-5-carboxamide (100 mg, 0.28 mmoles) in DMSO (6 mL) was added 4-(l-ethynyl)phenylacetate (1 eq) followed by triethylamine (3 eq), CuI (0.05 eq) and tetrakis (triphenylphosphine) palladium(O) (0.03 eq) and the reaction mixture was stirred at room temperature for 6 h. The reaction mixture was then diluted with water and extracted with ethyl acetate. The organic layer was then dried over Na2SO4, concentrated and purified by column chromatography to get 70 mg of the desired product. 1H NMR (DMSO-d6) δ 8.94 (br t, IH), 8.49 (d, J = 5.4 Hz, IH), 7.80-7.65 (m, 3H), 7.65-7.55 (m, IH), 7.32 (d, J = 7.5 Hz, IH), 7.25 (d, J= 8.4 Hz, 2H), 4.52 (d, J = 6.0 Hz, 2H), 2.61 (s, 3H), 2.29 (s, 3H). MS (m/z): 392.24 (M+H)+.
Step 3: N-5-(2-Pyridylmethyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5- carboxamide:
To a solution of 4-{2-[4-methyl-5-(2-pyridylmethylcarbamoyl)-l,3-thiazol-2-yl]-l-ethynyl}- phenylacetate (60 mg, 0.15 mmoles) in a mixture of THF, methanol and water (3:2:1, 6 mL respectively) was added lithium hydroxide hydrate (2 eq) and stirred the reaction mixture at room temperature for 4 h. Solvent was then evaporated from the reaction mixture on rotavapor, residue was neutralized with IN HCl and extracted with ethyl acetate. The organic layer was then dried over Na2SO4, concentrated and purified through column chromatography to get 35 mg of the desired product. 1H NMR (DMSO-d6) δ 10.2 (br s, IH), 8.90 (br t, IH), 8.50 (d, J= 3.9 Hz3 IH), 7.76 (br t, IH), 7.48 (d, J = 8.1 Hz, 2H), 7.32 (d, J = 7.8 Hz, IH), 7.30-7.25 (m, IH), 6.83 (d5 J= 8.1 Hz, 2H), 4.52 (d, J= 5.4 Hz, 2H), 2.59 (s, 3H).
Example 6 2-[(4-Hydroxy phenyl) ethynyl]- 4 -methyl- iV-(2-phenyl ethyl)-l,3-thiazole-5-carboxamide:
Figure imgf000040_0001
Step 1 : jV-5-phenethyl-2-iodo-4-rnethyl- 1 ,3-thiazole-5-carboxamide:
By following the similar procedure as described in step 1 of example 5 using intermediate 1 (0.5 g, 1.85 mmoles) and phenethylamine (1 eq) instead of 2-(aminomethyl) pyridine to get 400 mg of the desired product. 1H NMR (DMSO-d6) δ 8.29 (br, s, IH), 7.35-7.15 (m, 5H), 3.48-3.38 (q, J= 6.9 Hz5 2H), 2.79 (t, J= 6.9 Hz, 2H), 2.46 (s, 3H).
Step 2: 4 [( 4- Methyl -5-{[(2-phenyl ethyl)amino] -l,3-thiazol-2-yl)-l-ethynyl]-phenyl acetate
By following the similar procedure as described in step 2 of example 5, using 2-Iodo-4- methyl-iV-(2-ρhenylethyl)-l,3-thiazole-5-carboxamide (300 mg, 0.80 mmoles) instead ofN5- (2-pyridylmethyl)-2-iodo-4-methyl-l,3-thiazole-5-carboxamide to get 120 mg of the desired product.1H NMR (DMSOd6) δ 10.21 (br s, IH); 8.37 (br t, lH);7.70(d, J= 8.4 Hz, 2H); 7.46 (d, J == 8.4 Hz, 2H); 7.3Om5 5H); 6.82 (d, J = 8.7 Hz, 2H), 3.50-3.40 (m, 2H), 2.90-2.80 (m, 2H); 2.48 ( s, 3H); 2.29(s5 3H).
Step 3: 2-[(4-Hydroxy phenyl)ethynyl]-4-methyl-N-(2-phenylethyl)-l ,3-thiazole-5-carbox amide:
By following the similar deacetylation procedure as described in step 3, example 5 using 4 [( 4-nαethyl-5-{[(2-phenyl ethyl)ammo]-l,3-thiazol-2-yl)-l-ethynyl]-phenyl acetate (60 mg, 0.15 mmoles) to get 29 mg of the desired product. 1H NMR (DMSO-d6) δ 10.21 (br s, IH); 8.37 (br t5 IH); 7.46 (d, J= 8.4 Hz5 2H); 7.35-7.15 (m, 5H); 6.82 (d, J = 8.4 Hz, 2H), 3.50- 3.40 (m, 2H), 2.82 (t, J= 6.9 Hz, 2H); 2.47 ( s,3H). MS (m/z):- 363.25 (M+H)+.
Example 7 N-(4-Fluorobenzyl)-2-[(4-hydroxyρhenyl) ethynyl] - 4- methyl 1,3-thiazole- 5-carboxamide:
Figure imgf000041_0001
Step 1: 4-[(5-{[(4-Fluorobenzyl)amino]carbonyl}-4-methyl-l,3-thiazol-2-yl)ethynyl]phenyl acetate:
By following the similar procedure as described in step 2 of example 5 by using N-(4- fluorobenzyl)-2-iodo-4-methyl-l,3-thiazole-5-carboxamide (intermediate 2, 200 mg, 0.53 mmoles) instead of N5-(2-pyridylmethyl)-2-iodo-4-methyl- 1,3 -thiazole-5-carboxamide to get 120 mg of the desired product.1H NMR (CDCl3) δ 7.57 (d, J = 8.4 Hz, 2H) ; 7.35-7.30 (m, 2H); 7.11 (d, J= 8.7 Hz, 2H); 7.03 (t, J = 8.7 Hz, 2H), 6.03 (br s, IH); 4.57 (d, J= 5.4 Hz, 2H); 2.71 (s, 3H); 2.31 ( s, 3H); MS: 409.45 [M+H]+.
Step 2: N-(4-Fluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carbox- amide:
By following the similar procedure as described in step 3 of example 5 using 4-[(5-{[(4- fluorobenzyl)amino]carbonyl}-4-methyl-l,3-thiazol-2-yl) ethynyljphenylacetate (80 mg, 0.19 mmoles) to get 34 mg of the desired product. 1H NMR (CDCl3) 7.44 (d, J = 9.0 Hz, 2H); 7.38-7.28 (m, 2H); 7.03 (t, J= 8.1 Hz, 2H); 6.82 (d, J= 8.7 Hz, 2H); 6.05-5.98 (m, IH); 5.65- 6.55 (m, IH); 4.57(d, J= 6.0 Hz, 2H ); 2.70 (s, 3H). MS (m/z): 367.30 (M+H)+.
Example 8 2- [(4-Hydroxyphenyl)ethynyl] -4-methyl-iV-(3 -phenylpropyl)- 1 , 3 -thiazole-5 -carboxamide :
Figure imgf000041_0002
Step 1 : 4-[4- Methyl -5{[(3-phenylpropyl)amino]carbonyl}-l,3-thiazol-2-yl)-ethynyl phenyl acetate:
By following the similar procedure as described in step 2 of example 5 using 2-iodo-4- methyl-JV-(3 -phenylpropyl)- 1, 3 -thiazole-5-carboxamide (intermediate 3, 200 mg, 0.51 mmoles) instead of N5-(2-pyridylmethyl)-2-iodo-4-methyl- 1,3 -thiazole-5-carboxamide to get 148 mg of the desired product. 1H NMR (DMSOd6) δ 8.38 ( m, IH); 7.70 ( d, J = 8.4 Hz, 2H); 7.26-7.15 (m, 7H); 3.23 (q, J= 5.7 Hz, 2H); 2.62 (m, 5H); 2.28 (s, 3H); 1.81 (p, J= 7.2 Hz, 2H). Step 2: 2-[(4-Hydroxyphenyl)ethynyl]-4-niethyl-Λr-(3-ρhenylpropyl)-l,3-thiazole-5-carbox- amide:
By following the similar procedure as described in step 3 of example 5 using 4-[4-Methyl - 5{[(3-phenylpropyl)amino]carbonyl}-l,3-thiazol-2-yl)-ethynyl phenyl acetate (80 mg, 0.19 mmoles) to get 27 mg of the desired product. 1H NMR (CDCl3) δ 7.42 (d, J = 8.7 Hz, 2H) ; 7.30-7.15 (m, 5H); 6.83 (d, J= 8.4 Hz, 2H); 6.07 (s, IH); 5.71 (br s,lH); 3.49-3.42 (q, J= 6.3 Hz, 2H); 2.71(t, J =7.5 Hz, 2H); 2.65 (s, 3H); 1.96 ( p, J = 6.9 Hz, 2H); MS (m/z): 377.33 (M+H)+.
Example 9
N-5-[(lR)- 1 -Phenylethyl]-2-[2-(4-hydroxyphenyl)- 1 -ethynyl]-4-methyl- 1 ,3-thiazole-5- carboxamide:
Figure imgf000042_0001
Step 1: 4-[2- {4-Methyl-5-[( ii?)- 1 -phenylethylcarbamoyl]- 1 ,3-thiazol-2-yl} - 1 -ethynyl)phenyl acetate:
By following the similar procedure as described in step 2 of example 5 using 2-iodo-4- methyl-N-[(i?)-(+)(l-phenylethyl)]-l,3-thiazole-5- carboxamide (intermediate 14, 240 mg, 0.64 mmoles) instead of iV-5-(2-pyridylmethyl)-2-iodo-4-methyl-l,3-thiazole-5-carboxamide to get 130 mg of the desired product. 1H NMR (CDCl3) δ 7.57 (d, J= 8.4 Hz, 2H); 7.37-7.25 (m, 5H); 7.10 (d, J= 8.4 Hz, 2H); 5.94 (d, J= 6.9 Hz, IH); 5.25 (p, J= 6.9 Hz, IH); 2.69 ( s, 3H); 2.31 (s, 3H); 1.60 (d, J= 6.9 Hz, 3H).
Step 2: N-5-[(7i?)-l-Phenylethyl]-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole- 5-carboxamide:
By following the similar procedure as described in step 3 of example 5 using 4-[2-{4-methyl- 5-[(ii?)-l-phenylethylcarbamoyl]-l,3-thiazol-2-yl}-l-ethynyl)ρhenyl acetate (100 mg, 0.25 mmoles) to get 80 mg of the desired product. 1H NMR (CDCl3) δ 7.42 (d, J = 8.7 Hz5 2H) ; 7.38-7.25 (m, 5H); 6.82 (d, J = 8.7 Hz, 2H); 6.05-5.90 (m, 2H); 5.30-5.20 (m, IH) ; 2.68 (s, 3H); 1.63-1.60 ( br d, 3H); MS (m/z): 361.42(M-H)+.
Example 10 iV-5-[(;5)-l-Phenylethyl]-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5-carbox amide:
Figure imgf000043_0001
Step 1: ' 4-[2-{4-Methyl-5-[(16)-l-phenylethylcarbamoyl]-L3-thiazol-2-yl)-l-ethynyl)phenyl acetate:
By following the similar procedure as described in step 2 of example 5 using N-5-[(l S)-I- phenylethyl]-2-iodo-4-methyl-l,3-thiazole-5-carboxamide (intermediate 4, 250 mg5 0.67 mmoles) instead of iV-5-(2-pyridylmethyl)-2-iodo-4-methyl-l,3-tb.iazole-5-carboxamide to get 330 mg of the desired product. 1H NMR (CDCl3) δ 7.57 (d, J = 8.4 Hz5 2H); 7.40-7.25 (m, 5H); 7.10 (d, J= 8.7 Hz, 2H); 5.95 (d, J= 7.2 Hz, IH); 5.25 (p, J= 7.2 Hz, IH); 2.69 ( S5 3H); 2.31 (s, 3H), 1.61 (d, J= 6.9 Hz, 3H).
Step 2: 7V-5-[(i5)-l-phenylethyl]-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-tliiazole- 5-carboxamide:
By following the similar procedure as described in step 3 example 5 using 4-[2-{4-Methyl-5- [(l^-l-phenylethylcarbamoylj-l^-thiazol^-ylj-l-ethyny^phenyl acetate (80 mg, 0.2 mmoles) to get 45 mg of the desired product. 1H NMR (CDCl3) δ 7.40 (d, J = 8.1 Hz, 2H); 7.39-7.28 (m, 5H); 6.82 (d, J= 8.1 Hz, 2H); 6.16 (s, IH); 5.98 (d, J= 8.1 Hz, IH), 5.25 (p, J = 6.9 Hz,lH); 2.68 (s, 3H); 1.60 ( d, J= 6.3Hz, 3H); MS (m/z): 363.33(M+H)+.
Example 11 iV-(4-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide:
Figure imgf000043_0002
Step 1 : 4- [(5- { [(4-Chlorobenzyl)amino]carbonyl} -4-methyl- 1 ,3 -thiazol-2-yl)ethynyl]ρhenyl acetate:
By following the similar procedure as described in step 2 of example 5 using intermediate 5 (200 mg, 0.51 mmoles), to get 70 mg of the desired product. 1H NMR (CDCl3) δ 8.92 (m,lH); 7.71 (d, IH5 J= 8.1Hz); 7.39 (d, IH, J = 8.1Hz); 7.32(d, 2H, J= 8.4 Hz); 7.25 (d, 2H, J= 9.0 Hz); 4.41 (d, IH5 J= 5.7 Hz) 2.58 (s, 3H); 2.29(s, 2H). Ste^2;iV-(4-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5- carboxamide:
By following the similar procedure as described in step 3 of example 5 using 4-[(5-{[(4- Chlorobenzyl)amino]carbonyl}-4-methyl-l,3-thiazol-2-yl)ethynyl]phenyl ' acetate (50 mg, 0.118 mmoles) to get 14 mg of the desired product. 1H NMR (CDCl3) δ 10.20 (s, IH); 8.87 (m,lH); 7.47 (d, 2H, J= 8.4 Hz); 7.38 (d, 2H, J =8.4 Hz); 7.3 l(d, 2H, J = 7.8 Hz); 6.82 (d, 2H, J= 9.0 Hz); 4.40 (d, 2H, J= 5.4 Hz); 2.56 (s, 3H); MS (m/z): 383.54 (M+H)+.
Example 12
N- [ 1 -(4-Fluorophenyl)ethy 1] -2- [(4-hydroxypheny l)ethynyl] -4-methyl- 1 , 3 -thiazole-5 - carboxamide:
Figure imgf000044_0001
Step 1: 4-{[5-({[l-(4-Fluorophenyl)ethyl]amino}carbonyl)-4-methyl-l,3-thiazol-2-yl] ethynyl}phenylacetate :
By following the similar procedure as described in step 2 of example 5, using intermediate 6 (200 mg, 0.51 mmoles) to get 165 mg of the desired product. 1H NMR (CDCl3) δ 8.79 (d, IH, J =7.2 Hz); 7.70 (d, 2H, J =7.2 Hz); 7.37-7.42 (m, 2H); 7.24 (d, 2H, J=8.1 Hz); 7.14 (t, 2H, J =17.7 Hz); 5.07 (m, IH); 2.54 (s, 3H); 2.29 (s, 3H); 1.44(d, 3H, J =7.5 Hz)
Step 2: N-[l-(4-Fluorophenyl)ethyl]-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5- carboxamide:
By following the similar procedure as described in step 3 of example 5 using 4-{[5-({[l-(4- fluorophenyl)ethyl] amino } carbonyl)-4-methyl- 1 , 3 -thiazol-2-y 1] ethynyl } phenylacetate (50 mg, 0.12 mmoles) to get 14 mg of the desired product. 1H NMR (CDCl3) δ 10.20 (s, IH); 8.74 (d, IH, J =7.8 Hz); 7.47-7.41 (m, 4H); 7.14 (t, 2H, /=17.4 Hz); 6.81(d, 2H3 J= 8.4 Hz); 5.09 - 5.05 (m, IH); 2.52 (s, 3H); 1.44(d, 3H, J =6.6 Hz); MS (w/z):382.45(M+H)+.
Example 13 iV-(2,4-Difluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide:
Figure imgf000045_0001
Step 1 : 4-[(5-{[(2,4-Difluorobenzyl)amino]carbonyl}-4-methyl-l,3-thiazol-2-yl)ethynyl] phenylacetate:
By following the similar procedure as described in step 2 of example 5, using intermediate 7 (100 mg, 0.25 mmoles) to get 28 mg of the desired product. 1H NMR (CDCl3) δ 8.90 (t, IH); 7.71 (d, 2H, J = 8.4 Hz); 7.42-7.40 (m,lH); 7.24 (d, 3H, J = 8.4 Hz); 7.06 (t, IH); 4.42 (d, 2H); 2.57(s, IH); 2.29 (s, IH)
Step 2: τV-(2,4-difluorobenzyl)-2- [(4-hydroxyphenyl)ethynyl] -4-methyl- 1 ,3 -thiazole-5 - carboxamide:
By following the similar procedure as described in step 3 of example 5 using 4-[(5-{[(2,4- difluorobenzyl)amino]carbonyl}-4-methyl-l,3-thiazol-2-yl)ethynyl]phenylacetate (23 mg, 0.054 mmoles) to get 9 mg of the desired product. 1H NMR (CDCl3) δ 10.21 ( s,lH); 8.84 (t, IH); 7.47-7.39 (m, 3H); 7.21 (t, IH, J = 20.1Hz); 7.07(t, IH, J= 7.5Hz); 6.82 (d, 2H, J= 8.4 Hz); 4.41 (d, 2H, J= 4.8 Hz); 2.55(s, 3H).
Example 14
N- [2-(4-Fluorophenyl)ethyl] -2- [(4-hydroxyphenyl)ethynyl]-4-methyl- 1 ,3 -thiazole-5- carboxamide:
Figure imgf000045_0002
Step 1 : 4-{[5-({[2-(4-Fluorophenyl)ethyl]amino}carbonyl)-4-methyl-l,3-thiazol-2-yl] ethynyl } phenylacetate :
By following the similar procedure as described in step 2 of example 5 using intermediate 8 (150 mg, 0.38 mmoles) to get 85 mg of the desired product. 1H NMR (CDCl3)δ 8.41(t, IH); 7.70 (d, 2H, J= 8.4 Hz); 7.25 (m, 4H); 7.10(t, IH5 J= 17.7 Hz); 3.43 (m, 2H); 2.81 (t, 2H, J = 14.1 Hz); 2.29 (s, 3H).
Step 2: N- [2-(4-Fluorophenyl)ethyl] -2-[(4-hydroxyphenyl)ethynyl] -4-methyl- 1 ,3 -thiazole-5 - carboxamide: By following the similar procedure as described in step 3 of example 5 using 4-{[5-({[2-(4- fluorophenyl)ethyl]amino}carbonyl)-4-methyl-l,3-thiazol-2-yl]ethynyl}phenylacetate (80 mg, 0.19 mmoles) to get 21 mg of the desired product. 1H NMR (CDCl3) δ 10.21 (s, IH); 8.35 (t, IH); 7.46 (d, J= 8.4 Hz, 2H), 7.27-7.22 (m, 2H); 7.07(t, 2H, J= 7.5 Hz); 6.82 (d, 2H, J = 8.7 Hz); 3.44-3.42 (m, 2H); 2.81 (t, 2H, J = 13 Hz), 2.62 (s, 3H); MS (m/z): 382.82 (M+H)+-
Example 15 iV-(3-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide:
Figure imgf000046_0001
Step 1 : 4-[(5-{ [(3-Chlorobenzyl)amino]carbonyl}-4-methyl-l ,3-thiazol-2-yl)ethynyl]phenyl acetate:
By following the similar procedure as described in step 2 example 5 using intermediate 9 (150 mg, 0.38 mmoles) to get 90 mg of the desired product. 1H NMR (CDCl3) δ 8.94 (t, IH, J = 12.0 Hz); 7.71 (d, 2H, J= 9.0 Hz); 739-7.24 (m, 6H); 4.43(d, 2H, J= 5.4 Hz); 2.60 (s, 3H); 2.29 (s, 3H).
Step 2: iV-(3-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carbox- amide:
By following the similar procedure as described in step 3 of example 5 using 4-[(5-{[(3- chlorobenzyl)amino]carbonyl}-4-methyl-l,3-thiazol-2-yl)ethynyl]phenyl acetate (50 mg, 0.118 mmoles) to get 21 mg of the desired product. 1H NMR (CDCl3) δ 10.22 ( s,lH); 8.88 (t, IH, J= 11.7 Hz); 7.47 (d, 2H, J= 8.7 Hz); 7.39-7.25 (m, 4H); 6.83 (d, 2H, J= 8.7 Hz); 4.42 (d, 2H, J= 5.1 Hz); 2.57 (s, 3H); MS (m/z): 383.66 (M+H)+.
Example 16
2-[(4-Hydroxyphenyl)ethynyl]-N-(4-methoxybenzyl)-4-methyl-l,3-thiazole-5-carboxamide:
Figure imgf000046_0002
SteβJi 4-[(5-{[(3-Chlorobenzyl)amino]carbonyl}-4-methyl-l,3-thiazol-2-yl)ethynyl]phenyl acetate:
By following the similar procedure as described in step 2 of example 5 using intermediate 10 (150 mg5 0.386 mmoles) to get 55 mg of the desired product. 1H NMR (CDCl3) δ 8.85 (t, IH); 7.70 (d, 2H, J= 8.7 Hz); 7.24 (t, 2H, J= 14.1 Hz); 6.88 (d, 2H, J= 8.7 Hz); 4.35(d, 2H, J= 6.0 Hz); 3.72 (s, 3H); 2.57 (s, 3H); 2.29 (s,3H)
Step 2: 2-[(4~Hydroxyphenyl)ethynyl]-λr-(4-methoxybenzyl)-4-methyl- 1 ,3 -thiazole-5- carboxamide:
By following the similar procedure as described in step 3 of example 5 using 4-[(5-{[(4- methoxybenzyl)amino]carbonyl}-4-methyl-l,3-thiazol-2-yl)ethynyl]phenyl acetate (50 mg, 0.119 mmoles) to get 24 mg of the desired product. 1H NMR (CDCl3) δ 10.22 (s,lH); 8.80- 8.78 (m, IH); 7.47(d, 2H, J= 8.1 Hz); 7.22 (d, 2H, J= 8.4 Hz); 6.88-6.81 (m, 4H); 4.34 (d, 2H, J= 5.4 Hz); 3.72 (s, 3H); 2.55 (s,3H).
Example 17
2-[(4-Hydroxyphenyl)ethynyl]-4-methyl-iV-[4-(trifluoromethyl)benzyl]-l,3-thiazole-5- carbox amide:
Figure imgf000047_0001
Step_il 4-{[4-Methyl-5-({[4-(trifluoromethyl)benzyl]amino}carbonyl)-l,3-thiazol-2-yl] ethynyl }phenylacetate :
By following the similar procedure as described in step 2 of example 5 using intermediate 11 (100 mg, 0.23 mmoles) to get 55 mg of the desired product. 1H NMR (CDCl3) δ 8.99 (t, IH); 7.72-7.68 (m,4H); 7.52 (d, 2H, J= 8.4 Hz); 7.25 (d, 2H, J= 8.4 Hz); 4.51(d, 2H, J= 5.1 Hz); 2.60 (s, 3H); 2.29 (s,3H); MS (m/z): 459.34 (M+H)+.
Step_J2_i 2-[(4-Hydroxyphenyl)ethynyl]-4-methyl-7V-[4-(trifluoromethyl) benzyl] -1,3 -thiazole- 5-carboxamide:
By following the similar procedure as described in step 3 of example 5, using 4-{[4-Methyl- 5-({ [4-(trifluoromethyl)benzyl]amino}carbonyl)-l ,3-thiazol-2-yl] ethynyl }phenylacetate (50 mg, 0.11 mmoles) to get 14 mg of the desired product. 1H NMR (CDCl3) δ 10.23 ( s,lH); 8.93 (t, IH5 J= 6.0 Hz); 7.69 (d, 2H, J= 8.1 Hz); 7.53-7.46 (m,4H); 6.83 (d, 2H, J= 8.7 Hz); 4.50 (d, 2H3 J= 5.1Hz); 2.58 (s, 3H).
Example 18 iV-(2,6-Difluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l53-thiazole-5-carboxamide-.
Figure imgf000048_0001
Step 1 : 4-[(5-{ [(2,6-Difluorobenzyl)amino]carbonyl } -4-methyl- 1 ,3 -thiazol-2-yl)ethynyl] phenylacetate:
By following the similar procedure as described in step 2 example 5 using intermediate 12 (150 mg, 0.38 mmoles) to get 60 mg of the desired product. 1H NMR (CDCl3) δ 8.87 (t, IH, J = 6.0 Hz); 7.70 (d, 2H, J= 8.4 Hz); 7.37-7.41 (m, IH); 7.24(d, 2H, J= 9.0 Hz); 7.09 (t, 2H, J = 15.6 Hz); 4.48 (d, 2H, J= 5.1 Hz); 2.53 (s, 3H); 2.29 (s, 3H).
Step 2: iV-(2,6-Difluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5- carboxamide:
By following the similar procedure as described in step 3 of example 5 using 4-[(5-{[(2,6- difiuorobenzyl)amino] carbonyl } -4-methyl- 1 ,3 -thiazol-2-y l)ethynyl]phenylacetate (5 Omg, 0.18 mmoles) to get 30 mg of the desired product. 1H NMR (CDCl3) δ 10.22 ( s,lH); 8.79- 8.81 (m, IH); 7.46 (d, 2H, J= 8.1 Hz); 7.41-7.36 (m, IH); 7.08 (t, 2H, J= 15.6 Hz); 6.82 (d, 2H, J= 8.4 Hz); 4.47 (d, 2H, J= 4.8 Hz); 2.50 (s, 3H).
Example 19 τV-(2-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide:
Figure imgf000048_0002
Step!:. 4-[(5-{[(2-Chlorobenzyl)amino]carbonyl}-4-methyl-l,3-thiazol-2-yl)ethynyl]phenyl acetate:
By following the similar procedure as described in step 2 of example 5 using intermediate 13 (200 mg, 0.51 mmoles) to get 80 mg of the desired product. 1H NMR (CDCl3) δ 8.92 (br s, IH); 7.71 (d, J= 8.4 Hz, 2H); 7. 45 (d, J = 6.9 Hz, IH); 7.40-7.30 (m, 3H); 7.25 (d, J = 8.7 Hz, 2H); 4.49 (d, J= 5.4 Hz, 2H); 2.60 (s, 3H); 2.29 (s, 3H).
Steβl: N-(2-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-lJ3-thiazole-5- carboxamide:
By following the similar procedure as described in step 3 of example 5 using 4-[(5-{[(2- Chlorobenzyl)amino]carbonyl}-4-methyl-l,3-thiazol-2-yl)ethynyl]phenyl acetate (60 mg, 0.14 mmoles) to get 27 mg of the desired product. 1H NMR (DMSOd6) δ 10.23 ( s,lH); 8. 85 (br s, IH); 7.55-7.45 (m, 3H); 7.35-7.25 (m, 3H); 6.83 (d, J= 8.4 Hz, 2H); 4.49 (d, J= 5.4 Hz, 2H); 2.58 (s, 3H); MS (m/z); 383.56(M+H)+.
Example 20 iV-5-(3-Phenylpropyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3-thiazole-5- carboxamide:
Figure imgf000049_0001
Step 1: 4-{2-[5-(3-Phenylpropylcarbamoyl)-4-trifiuoromethyl-l,3-thiazol-2-yl]-l-ethynyl}- phenylacetate:
To a solution of 2-iodo-N-(3-phenylpropyl)-4-(trifluoromethyl)-l,3-thiazole-5- carboxamide (intermediate 23, 100 mg, 0.227 mmoles) in dry DMSO (4 mL) was added 4-(l- ethynyl)phenylacetate (intermediate 16, 1 eq) followed by copper iodide (0.04 eq), tetrakis tripheylphosphine palladium(O) (0.03 eq) and triethylamine (3 eq) and the reaction mixture was stirred at room temperature for overnight. The reaction mixture was then diluted with ethyl acetate (30 mL), washed with water (2 x 20 mL), dried over Na2SO4 and concentrated. The crude was then purified by column chromatography to get 85 mg of the title product. 1H NMR (DMSO-de) δ 9.06 (br s, IH), 7.77 (d, J = 8.4 Hz, 2H), 7.30-7.15 (m, 7H), 3.30-3.20 (m, 2H), 2.61 (t, J= 6.9 Hz, 2H), 2.29 (s, 3H), 1.78 (m, 2H). MS (m/z); 473.57 (M+H)+.
Step 2: iV-5-(3-Phenylpropyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifiuoromethyl-l,3- thiazole-5-carboxamide:
To a solution of 4-{2-[5-(3-Phenylpropylcarbamoyl)-4-trifluoromethyl-l,3-thiazol-2-yl]-l- ethynyl}phenylacetate (70 mg, 0.15 mmoles) in a mixture of THF, methanol and water (3:2:1, 6 mL respectively) was added lithium hydroxide hydrate (2 eq) and stirred the reaction mixture at room temperature for 4 h. Evaporated the solvent and the obtained residue was neutralized with IN HCl and extracted with ethyl acetate. The organic layer was then dried over Na2SO4, concentrated and purified through column chromatography to get 40 mg of the desired product. 1H NMR (DMSOd6) δ 10.31 (s, IH), 9.03 (br s, IH), 7.53 (d, J= 8.4 Hz, 2H), 7.30-7.15 (m, 5H), 6.84 (d, J = 8.1 Hz, 2H), 3.30-3.20 (m. 2H), 2.60 (t, J = 8.4 Hz 2H), 1.85-1.75 (m, 2H).
Example 21 iV-5-Phenethyl-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3-thiazole-5-carbox- amide:
Figure imgf000050_0001
Step 1 : 4-[2-(5-Phenethylcarbamoyl-4-trifluoromethyl-l,3-thiazol-2-yl)-l-ethynyl]-phenyl acetate:
By following the similar procedure as described in step 1 of example 20, using 2-iodo-iV-(2- phenylethyl)-4-(trifluoromethyl)-l,3-thiazole-5-carboxamide (intermediate 24, 160 mg, 0.37 mmoles) instead of 2-iodo-N-(3-phenylpropyl)-4-(trifluoromethyl)-l,3-thiazole-5- carboxamide to get 0.16 g of the desired product. 1H NMR (DMSOd6) δ 9.08 (t, J= 5.4 Hz, IH), 7.77 (d, J - 8.7 Hz, 2H), 7.35-7.17 (m, 7H), 3.50-3.44 (q, J = 6.9 Hz, 2H), 2.81 (t, J = 7.2 Hz 2H), 2.29 (s, 3H); MS (m/z); 459.27 (M+H)+.
Step_2LN-5-Phenethyl-2-[2-(4-hydroxyphenyl)- 1 -ethynyl]-4-trifluoromethyl- 1 ,3-thiazole-5- carboxamide:
By following the similar procedure as described in step 2 of example 20, using 4-[2-(5- phenethylcarbamoyl-4-trifluoromethyl-l ,3-thiazol-2-yl)-l -ethynylj-phenylacetate (60 mg, 0.131 mmoles) instead of 4-{2-[5-(3-phenylpropylcarbamoyl)-4-trifluoromethyl-l,3-thiazol- 2-yl]-l-ethynyl} -phenyl acetate to get 35 mg of the title compound. 1H NMR (DMSOd6) δ 10.32 (s, IH), 9.06 (br s, IH), 7.53 (d, J = 8.1 Hz, 2H), 7.35-7.20 (m, 5H), 6.85 (d, J = 8.4 Hz, 2H), 3.50-3.42 (q, J= 6.9 Hz, 2H), 2.80 (t, J= 7.2 Hz, 2H); MS (m/z): 417.17 (M+H)+ .
Example 22 iV-5-(4-Fluorobenzyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3-thiazole-5- carboxamide:
Figure imgf000051_0001
Step 1 : 4-{2-[5-(4-Fluorobenzylcarbamoyl)-4-trifluoromethyl-l,3-thiazol-2-yl]-l-ethynyl}- phenylacetate:
By following the similar procedure as described in step 1 of example 20 using 2-iodo-JV-(4- fluorobenzyl)-4-(trifluoromethyl)-l,3-thiazole-5-carboxamide (intermediate 25, 100 mg, 0.23 mmoles) instead of 2-iodo--\r-(3-phenylpropyl)-4-(trifluoromethyl)-l,3-thiazole-5- carboxamide to get 0.14 g of the desired product. 1H NMR (DMSOd6) δ 9.52 (br s, IH), 7.77 (d, J= 8.7 Hz, 2H), 7.40-7.30 (m, 2H), 7.28 (d, J= 9.0 Hz, 2H), 7.20-7.10 (m, 2H), 4.43 (d, J = 5.4 Hz, 2H), 2.29 (s, 3H); MS (m/z): 462.94 (M)+.
Step 2: N5-(4-Fluorobenzyl)-2-[2-(4-hydroxyphenyl)-l -ethynyl]-4-trifluoromethyl-l ,3- thiazole-5-carboxamide:
By following the similar procedure as described in step 2 of example 20 using 4-{2-[5-(4- fluorobenzylcarbamoyl)-4-trifluoromethyl-l,3-thiazol-2-yl]-l-ethynyl}-phenylacetate (60 mg, 0.13 mmoles) instead of 4-{2-[5-(3-phenylpropylcarbamoyl)-4-trifluoromethyl-l,3- thiazol-2-yl]-l-ethynyl} -phenyl acetate to get 35 mg of the title compound. 1H NMR (DMSOd6) δ 10.30 (s, IH), 9.50 (br s, IH), 7.53 (d, J = 8.1 Hz, 2H), 7.40-7.30 (m, 2H), 7.20-7.10 (m, 2H), 6.84 (d, J = 8.7 Hz, 2H), 4.43 (d, J = 5.7 Hz, 2H); MS (m/z): 421.15 (M+H)+ .
Example 23 iV-5-(4-Tnfluoromethylbenzyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3- thiazole- 5-carboxamide :
Figure imgf000051_0002
Step 1: 4-|2-["4-Trifluoromethvl-5-(4-trifluoromethylbenzylcarbamoyl)-l,3-thiazol-2-yll-l- ethynyl } -phenylacetate :
By following the similar procedure as described in step 1 of example 20 using 2-iodo-JV-(4- trifluoromethylbenzyl)-4-(trifluoromethyl)- 1 ,3 -thiazole-5 -carboxamide (intermediate 26, 150 mg, 0.31 mmoles) instead of 2-iodo-7V-(3-phenylpropyl)-4-(trifluoromethyl)-l,3-thiazole-5- carboxamide to get 0.20 g of the desired product. 1H NMR (DMSOd6) δ 9.61 (s, IH)5 7.76 (d, J= 8.7 Hz, 2H), 7.72 (d, J- 7.8 Hz, 2H), 7.51 (d, J= 7.8 Hz, 2H), 7.27 (d, J = 8.4 Hz, 2H), 4.54 (d, J= 6.0 Hz, 2H), 2.29 (s, 3H); MS irn/z): 513.14 (M+H)+.
Step 2 : JV-5-(4-Trifluoromethvlbenzvl)-2-["2-(4-hvdroxyphenvl)- 1 -ethynyl]-4-trifluorornethyl- 1 ,3-thiazole-5-carboxamide:
By following the similar procedure as described in step 2 of example 20, using 4-{2-[4- trifluoromethyl-5-(4-trifluoromethylbenzylcarbamoyl)-l,3-thiazol-2-yl]-l-ethynyl}-phenyl acetate (50 mg, 0.098 mmoles) instead of 4-{2-[5-(3-phenylpropylcarbamoyi)-4- trifluoromethyl-l,3-thiazol-2-yI]-l-ethynyl}-phenyl acetate to get 35 mg of the title compound. 1H NMR (DMSO-d6) δ 10.30 (s, IH), 9.58 (br s, IH), 7.71 (d, J= 7.2 Hz, 2H), 7.60-7.50 (m, 4H), 6.84 (d, J = 8.4 Hz, 2H), 4.53 (d, J = 6.9 Hz, 2H). MS (m/z): 471.19 (M+H)+ .
Example 24
N-5-(4-Methoxybenzyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3-thiazole-5- carboxamide:
Figure imgf000052_0001
Step 1 : 4-{2-r5-(4-Methoxybenzylcarbamoyl)-4-trifluoromethyl- 1 ,3 -thiazol-2-yl]- 1 -ethynyl } - phenylacetate:
By following the similar procedure as described in step 1 of example 20 using 2-iodo-iV-(4- methoxybenzyl)-4-(trifluoromethyl)- 1,3 -thiazole-5 -carboxamide (intermediate 27, 130 mg, 0.29 mmoles) instead of 2-iodo-N-(3-phenylpropyl)-4-(trifluoromethyl)-l,3-thiazole-5- carboxamide to get 0.17 g of the desired product. 1H NMR (DMSOd6) δ 9.44 (br s, IH), 7.76 (d, J = 8.4 Hz, 2H), 7.27 (d, J= 9.0 Hz, 2H)5 7.21 (d, J= 8.4 Hz, 2H), 6.89 (d, J = 8.1 Hz, 2H)5 4.37 (d, J= 4.5 Hz5 2H), 3.73 (s, 3H), 2.29 (s, 3H). MS (m/z): 475.28 (M+H)+.
Ste^2i_iV-5-(4-niethoxybenzyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3- thiazole-5 -carboxamide :
By following the similar procedure as described in step 2 of example 20, using 4-{2-[5-(4- methoxybenzylcarbamoyl)-4-trifluoromethyl- 1 ,3 -thiazol-2-yl]- 1 -ethynyl } -phenylacetate (60 mg, 0.126 mmoles) instead of 4-{2-[5-(3-Phenylpropylcarbamoyl)-4-trifluoromethyl-l,3- thiazol-2-yl]-l -ethynyl} -phenylacetate to get 30 mg of the title compound. 1H NMR (DMSO- d6) δ 10.30 (s, IH), 9.41 (br s, IH)5 7.52 (d, J= 8.1 Hz, 2H)5 7.21 (d, J= 8.11Hz, 2H), 6.89 (d, J= 8.7 Hz5 2H), 6.84 (d, J= 8.4 Hz5 2H), 4.36 (d, J= 6.0 Hz, 2H), 3.73 (s, 3H). MS (m/z): 433.42 (M+H)+.
Example 25 iV-5-Benzyl-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3-thiazole-5-carbox- amide:
Figure imgf000053_0001
Step 1 : 4-{2-[5-(Benzylcarbamoyl)-4-trifluoromethyl-l,3-thiazol-2-yl]-l-ethynyl}-phenyl acetate:
By following the similar procedure as described in step 1 of example 20 using 2-iodo-iV- benzyl-4-(trifluoromethyl)-l,3-thiazole-5-carboxamide (intermediate 28, 150 mg, 0.36 mmoles) instead of 2-iodo-iV-(3-phenylpropyl)-4-(trifluoromethyl)-l,3-thiazole-5- carboxamide to get 0.17 g of the desired product. 1H NMR (DMSO-d6) δ 9.52 (br s, IH)5 7.76 (d, J= 8.7 Hz5 2H)5 7.35-7.20 (m, 7H)5 4.45 (d, J= 6.0 Hz5 2H)5 2.29 (s, 3H).
Step 2: JV-5-Benzvl-2-r2-(4-hydiOXvphenvl)-l -ethvnvll-4-trifluoromethvl-l .3-thiazole-5- carboxamide:
By following the similar procedure as described in step 2 of example 20 using 4-{2-[5- (benzylcarbamoyl)-4-trifluoromethyl- 1 ,3 -thiazol-2-yl]- 1 -ethynyl } -phenylacetate (60 mg, 0.135 mmoles) instead of 4-{2-[5-(3-Phenylpropylcarbamoyl)-4-trifluoromethyl-l,3-thiazol- 2-yl]-l-ethynyl}-phenyl acetate to get 30 mg of the title compound. 1H NMR (DMSO-d6) δ 10.32 (s, IH)5 9.50 (t, J= 5.4 Hz, IH), 7.53 (d, J= 8.1 Hz, 2H), 7.35-7.20 (m, 5H), 6.84 (d, J = 8.1 Hz, 2H), 4.44 (d, J= 6.0 Hz, 2H).
Example 26 4-Cyclopropyl-2-[(4-hydroxyphenyl) ethynyl]-iV-plienyl propyl- 1 ,3-thiazole-5-carboxamide:
Figure imgf000054_0001
To a solution of intermediate 29 (100 mg, 0.35 mmoles) in THF, was added DIPEA (3 eq), DMAP (0.1 eq), HOBT (1 eq) and EDCI (1.5 eq). Then 3-ρhenyl propylamine (1 eq) was added and stirred the reaction mixture for 12 h at room temperature. The reaction mixture was then quenched in water, extracted with ethyl acetate and concentrated to get 22 mg of desired product. 1H NMR (DMSO-d6) δ 10.19 (s,lH); 8.36 (s,lH); 7.44 (d, 2H, J= 7.8 Hz); 7.15-7.26 (m, 5H); 6.82 (d, 2H, J = 7.8 Hz); 3.23 (m, 2H); 2.73 (m, IH); 2.60 (t, 2H); 1.81 (m, 2H); 1.00 (m, 2H); 0.94 (m, 2H).
Example 27
4-Cyclopropyl-N-(4-fluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-l,3-thiazole-5-carbox- amide:
Figure imgf000054_0002
The title compound was prepared by following the similar procedure as described in example 26 by using intermediate-29 (100 mg, 0.35 mmoles) and 4-fluoro benzylamine (1 eq) to get 20 mg of the desired product. 1H NMR (DMSO-d6) δ 10.21(s, IH); 8.89 (t, IH); 7.45 (d, 2H, J= 8.7 Hz); 7.31 (t, 2H, J = 6.0 Hz); 7.14 (t, 2H, J = 17.7 Hz); 6.82 (d, 2H, J = 8.7 Hz); 4.38 (d, 2H, J= 5.7 Hz); 2.80 (m,lH); 1.01 (m, 2H); 0.95 (m, 2H)
Example 28
N-[2-(4-Fluorophenoxy)ethyl]-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5- carboxamide:
Figure imgf000055_0001
a) 4-{ [5-({ [2-(4-fluorophenoxy)ethyl]amino}carbonyl)-4-methyl-l,3-thiazol-2-yl]ethynyl} phenylacetate:
To the solution of intermediate 30 (150 mg, 0.37 mmoles) in DMSO was added CuI and Pd(pph3)4 and TEA followed by addition of 4-ethynylphenylacetate and stirred the reaction mixture at room temperature for 6 h. Then quenched the reaction mixture in ice cold water and extracted with ethyl acetate then the organic layer was dried over anhydrous sodium sulphate and concentrated to get crude product which was further purified by column chromatography to get 100 mg of the desired product. 1H NMR (CDCl3) δ 8.57 (t, IH); 7.70 (d, 2H5 J = 8.4 Hz); 7.24 (d, 2H5 J = 8.1Hz); 7.13 (m, 2H); 6.94 (m, 2H); 4.07 (t, 2H, J = 10.8 Hz); 3.57 (d, 2H, J= 5.1Hz); 2.56 (s, 3H); 2.29 (s, 3H). b) N-[2-(4-Fluorophenoxy)ethyl]-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5- carboxamide:
To the solution of 4-{[5-({[2-(4-fluorophenoxy)ethyl]amino}carbonyl)-4-methyl-l,3-thiazol- 2-yl]ethynyl}phenylacetate (80 mg, 0.18 mmoles) in THF5 water and methanol was added LiOH-H2O. Stirred the reaction mixture for 2 h at room temperature. Then solvent was distilled out and acidified with dilute HCl and extracted with ethyl acetate. Then the organic layer was dried over Na2SO4 and concentrated to get crude product which was purified by column chromatography to get 50 mg of the desired compound. 1H NMR (CDCl3) δ 10.23 (br s, IH); 8.53 (t, IH); 7.46 (d, 2H, J= 8.4 Hz); 7.09 (m, 2H); 6.96 (m, 2H); 6.82 (m, 2H); 4.07 (s, 2H); 3.58 (m, 2H); 2.55 (s, 3H); MS (m/z):397.21(M+H)+.
Example 29 2-[(4-Hydroxyphenyl)ethynyl]-4-methyl-N-(2-phenoxyethyl)-l,3-thiazole-5-carboxamide:
Figure imgf000055_0002
a) 4-[(4-Methyl-5- { [(2-phenoxyethyl)amino]carbonyl} - 1 ,3-thiazol-2-yl)ethynyl]phenyl acetate: The title compound was prepared by following the similar procedure as described in step 'a' of example 28 using intermediate 31 (160 mg, 0.41 mmoles) to get 100 mg of the desired compound. 1H NMR (CDCl3) δ 8.58 (t, IH); 7.70 (d, 2H3 J =8.4 Hz); 7.26 (m, 4H); 6.92 (m, 3H); 4.09 (t, 2H, J= 9.0 Hz); 3.59 (m, 2H); 2.57 (s, 3H); 2.29 (s, 3H). b) 2-[(4-Hydroxyphenyl)ethynyl]-4-methyl-N-(2-phenoxyethyl)-l,3-thiazole-5-carboxamide:
This compound was prepared by following the similar procedure as described in step 'b' of example 28, using 4-[(4-methyl-5-{[(2-phenoxyethyl)amino]carbonyl}-l,3-thiazol-2- yl)ethynyl] -phenyl acetate (150 mg, 0.36 mmoles) to get 80 mg of the target compound. 1H NMR (CDCl3) δ 10.23 (br s, IH); 8.54 (m, IH); 7.47 (d, 2H, J= 8.4 Hz); 7.27 (m, 2H); 6.82 (m, 5H); 4.07-4.08 (s, 2H); 3.58 (s, 2H); 2.55 (s, 3H); MS (m/z):37933 (M+H)+.
Example 30 iV-(2,4-Dichlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide:
Figure imgf000056_0001
a ) 4-[(5-{[(2,4-Dichlorobenzyl)amino]carbonyl}-4-methyl-l,3-thiazol-2-yl)ethynyl]phenyl acetate:
The title compound was prepared by following the similar procedure as described in step 2 of example 5 using intermediate 32 (200 mg, 0.47 mmoles) to get 150 mg of the desired product. 1U NMR (CDCl3) δ 8.93 (t, IH); 7.69 (d, 2H, J = 8.4 Hz); 7.62 (s, IH); 7.36-7.43 (m, 2H); 7.23 (d, 2H, J= 8.4 Hz); 7.46 (d, 2H, J= 5.4 Hz); 2.59 (s, 3H); 2.29 (s, 3H). b) iV-(2,4-Dichlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5carbox- amide
The title compound was prepared by following the similar procedure as described in step 3 of example 5 using 4-[(5-{[(2,4-dichlorobenzyl)amino]carbonyl}-4-methyl-l,3-thiazol-2- yl)ethynyl]phenylacetate (100 mg, 0.218 mmoles) to get 70 mg of the desired compound. 1H NMR (CDCl3) δ 10.23 (s, IH); 8.78 (t, IH); 7.61 (s, IH); 7.46 (d, 2H, J= 8.4 Hz); 7.40-7.35 (m, 2H); 6.82 (d, 2H, J =8.1 Hz); 4.45 (d, 2H, J = 5.4 Hz); 2.57 (s, 3H); MS (m/z): 415.68 (M+H)+. Pharmacological activity
The general values of the compounds in treating diseases or conditions may be established in industry standard animal models for demonstrating the efficacy of compounds described herein in treating the diseases and/or conditions described herein. The compounds of the present invention may be tested for their inhibitory activity for SCD, preferable SCDl, following the procedures known to a person ordinary skill in the art. Therefore, any process for measuring the activity of SCD enzymes including, for example, mouse or human SCD enzymes, may be utilized to assay the activity of the compounds useful in the methods of the present invention in inhibiting said SCD enzymes. As example, the following protocol was employed for testing compounds of the present invention. This protocol is illustrative and is not meant to limit to the scope of the present invention.
The identification of compounds as SCDl inhibitors was carried out using microsomal SCDl enzyme by the method of Barbara R Talamo et.al Analytical Biochemistry., (1969), 29, 300-304. In this assay the microsomal SCDl enzyme desaturates its substrate (American Radiochemicals) Stearoyl CoA which is tritiated at C9 and ClO positions.
Test compounds were dissolved in dimethylsulfoxide and tested at 10 μM final concentration. Before substrate addition, the test compound or standard reference compound (conjugated linoleic acid at 100 μM final concentration) were preincubated in reaction buffer with the enzyme for 10 minutes at 30 0C with shaking. Reaction buffer was essentially as described by Mark G Obukowicz, et ah, JPET, (1998), 287, 157-166, except that the MgCl2, ATP (Sigma) and CoA (Sigma) concentrations were changed to 4.9 mM, 7.2 mM and 0.54 mM respectively. The desaturation reaction was initiated by addition of 0.5 μCi of 3H stearoyl CoA and incubated at 37 0C for 30 minutes with shaking. A control reaction was set without any test compound / reference inhibitor to capture maximum enzymatic activity in the assay. Inhibition of enzyme activity was calculated as a percent of this control reaction giving maximum catalysis. The values are as given in table 1.
The IC50 (nM) values of the compounds are set forth in Table 1 wherein "A" refers to an IC50 value of less than 100 nM, "B" refers to IC50 value in range of 100.01 - 250 nM, "C" refers to an IC50 value in range of 250.01 - 500 nM and "D" refers to an IC50 value of more than 500 nM. Table 1 : Compounds ICso (nM) values in ranges:
Figure imgf000058_0001
Figure imgf000059_0001
nd - not determined
Whole cell based assay to screen for agents that differentially modulate SCD-I activity present in different tissues.
The whole cell based assay was adapted to screen for agents that differentially modulate SCD-I activity present in different tissues. Two cell lines namely human liver cell line (hepatocellular carcinoma HepG2) and human skin cell line (epidermal carcinoma A431) were used. HepG2 cells were seeded in a 24 well plate in complete MEM medium. A431 cells were seeded in a 12 well plate in complete DMEM medium. HepG2 cells were induced with LXR agonist T0901317 in medium containing 4.5 gm/litre glucose and 0.1% fatty acid free BSA for 3 days with media change every day (Wang et ah, Journal of Lipid Research, (2004), 41, 972-980). A431 cells were not induced. The cells were preincubated in plain medium containing 0.1 nM to 10 μM concentrations of potential SCD-I modulatory compounds for 15 - 30 minutes at 37 °C and further challenged with 0.25 to 7.5 μCi tritiated Stearoyl CoA. The cells were incubated for last 6 hours in 5% CO2 incubator at 37 °C or in specific embodiments for 4 h to 30 h. At the end of the incubation, the incubation medium was collected into tubes. Dowex AG 1-X8 resin pre-equilibrated with distilled ethanol: water was added to the tubes to separate the unconsumed substrate from the labeled water. The tubes were then vortexed for 5 minutes and centrifuged at 14000 rpm for 20 minutes at room temperature. The supernatant from the tubes was mixed with the scintillation fluid and radioactivity counted in the Packard topcount scintillation counter. Counts obtained were normalized per million cells. Inhibition of enzyme activity was calculated as the percent of maximum reaction control that contained no test compound. For active compounds, EC35 was calculated from dose response curve by non linear regression analysis using GraphPadPRISM software. The ratio of EC35 for skin cells to EC35 for liver cells was calculated. The EC35 values for liver and skin cells along with their ratios are given in Tables 2.
Table 2: Compounds Selective For Liver Over Skin
Figure imgf000060_0001

Claims

WE CLAIM:
1. The compound of the formula (I) :
Figure imgf000061_0001
or pharmaceutically acceptable salts thereof; wherein R is hydrogen, substituted or unsubstituted alkyl, or substituted or unsubstituted cycloalkyl;
Ri is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkyl, fully or partially substituted haloalkyl, substituted or unsubstituted haloalkyloxy, fully or partially substituted haloalkyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, or substituted or unsubstituted heteroaryl;
R2 is substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, substituted or unsubstituted cycloalkyl, or substituted or unsubstituted heterocyclyl; wherein substituents are independently selected from halogen, nitro, cyano, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkyl, fully or partially substituted haloalkyl, substituted or unsubstituted haloalkyloxy, fully or partially substituted haloalkyloxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic group, or substituted or unsubstituted heteroaryl; at each occurrence R3 is independently selected from hydrogen, hydroxyl, cyano, nitro, halogen, acetyl, acetoxy, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted alkoxy, substituted or unsubstituted haloalkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cyclcoalkylalkyl, substituted or unsubstituted cyclcoalkyloxy, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclyl, substituted or unsubstituted alkoxyalkyl, substituted or unsubstituted alkoxyaryl, substituted or unsubstituted arylalkyl, -0-C(O)-R', -C(O)NRaRb, -SONRaRb, -SO2NRaRb, -OR8, -COORa, -C(O)Ra, -C(S)R3, -C(O)ONRaRb, -NRaC(O)ORb, - NRaRb, -NRaC(O)Rb, or -NRaCONRaRb; at each occurrence Ra and Rb may be same or different and are independently selected from hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl, substituted or unsubstituted haloalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted cycloalkylalkyl, substituted or unsubstituted cycloalkenyl, substituted or unsubstituted cycloalkenylalkyl, substituted or unsubstituted aryl, substituted or unsubstituted arylalkyl, substituted or unsubstituted heteroaryl, substituted or unsubstituted heteroarylalkyl, substituted or unsubstituted heterocyclyl, or substituted or unsubstituted heterocyclylalkyl;
R' is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, or substituted or unsubstituted heterocyclyl;
'n' is an integer selected from 1 to 5, both inclusive and
L is (Ci-C6) alkylene linker which may be further substituted with halogen or alkyl.
2. The compounds according to claim 1, wherein R1 is substituted or unsubstituted alkyl or cycloalkyl.
3. The compounds according to claim 1, wherein R3 is hydroxyl.
4. The compounds according to claim 1, wherein R2 is substituted or unsubstituted aryl.
5. The compounds according to claim 1, wherein L is (Ci-C6) alkylene linker which is optionally substituted with alkyl.
6. The compound selected from:
N-5-Benzyl-2-[2-(3-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5-carboxamide; iV-5-Benzyl-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5-carboxamide; iV-5-(3-Pyridylmethyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5- carboxamide;
N-5-(3-Pyridylmethyl)-2-[2-(3-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5- carboxamide; iV-5-(2-Pyridylmethyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l53-thiazole-5- carboxamide;
2-[(4-Hydroxy phenyl) ethynyl]- 4 -methyl- N- (2-phenyl ethyl)-l,3thiazole-5-carboxamide; iV-(4-Fluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl l,3-thiazole-5-carboxamide; 2-[(4-Hydroxyphenyl)ethynyl]-4-methyl-N-(3-phenylpropyl)-l,3-thiazole-5-carboxamide; iV-5-[(2i?)-l-Phenylethyl]-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5- carboxamide;
N-5-[(7S)-l-Phenylethyl]-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-methyl-l,3-thiazole-5- carboxamide;
Λ/-(4-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide;
N-[l-(4-Fluorophenyl)ethyl]-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5- carboxamide; iV-(2,4-Difluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide; iV-[2-(4-fluorophenyl)ethyl]-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5- carboxamide;
N-(3-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide; 2-[(4-Hydroxyphenyl)ethynyl]-iV-(4-methoxybenzyl)-4-methyl-l,3-thiazole-5-carboxamide;
2-[(4-Hydroxyphenyl)ethynyl]-4-methyl-iV-[4-(trifluoromethyl)benzyl]-l,3-thiazole-5- carboxamide;
ΛL(2,6-Difluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide; N-(2-Chlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl] -4-methyl- 1 ,3 -thiazole-5 -carboxamide; iV-5-(3-Phenylpropyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3-thiazole-5- carboxamide; iV-5-Phenethyl-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3-thiazole-5- carboxamide; iV-5-(4-Fluorobenzyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3-thiazole-5- carboxamide; JV-5-(4-Trifluoromethylbenzyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3- thiazole-5-carboxamide;
N-5-(4-Methoxybenzyl)-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3-thiazole-5- carboxamide; iV-5-Benzyl-2-[2-(4-hydroxyphenyl)-l-ethynyl]-4-trifluoromethyl-l,3-thiazole-5- carboxamide;
4-Cyclopropyl-2-[(4-hydroxyphenyl) ethynyl]-iV-phenyl propyl- 1 ,3-thiazole-5-carboxamide;
4-Cyclopropyl-iV-(4-fluorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-l,3-thiazole-5- carboxamide;
N-[2-(4-Fluorophenoxy)ethyl]-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5- carboxamide;
2-[(4-Hydroxyphenyl)ethynyl]-4-methyl-iV-(2-phenoxyethyl)-l,3-thiazole-5-carboxamide and iV-(2,4-Dichlorobenzyl)-2-[(4-hydroxyphenyl)ethynyl]-4-methyl-l,3-thiazole-5-carboxamide or pharmaceutically acceptable salt thereof.
7. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
8. A method of treating a disease, disorder or syndrome mediated by stearoyl CoA desaturase 1 in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of any one of claim 1 to 7.
9. The method of claim 8, wherein the disease, condition or disorder is selected from obesity, appetite disorder, diabetes, impaired glucose tolerance, insulin resistance, a lipid disorder, metabolic syndrome and fatty liver disease.
10. The method of claim 9, wherein the disorder is obesity.
PCT/IB2009/006146 2008-07-16 2009-07-03 Thiazole derivatives as stearoyl coa desaturase inhibitors WO2010007482A2 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
IN1496MU2008 2008-07-16
IN1496/MUM/2008 2008-07-16
US8783308P 2008-08-11 2008-08-11
US61/087,833 2008-08-11
IN1881/MUM/2008 2008-09-05
IN1881MU2008 2008-09-05
US9726808P 2008-09-16 2008-09-16
US61/097,268 2008-09-16
IN2381MU2008 2008-11-10
IN2381/MUM/2008 2008-11-10
US11943608P 2008-12-03 2008-12-03
US61/119,436 2008-12-03

Publications (2)

Publication Number Publication Date
WO2010007482A2 true WO2010007482A2 (en) 2010-01-21
WO2010007482A3 WO2010007482A3 (en) 2010-12-02

Family

ID=41550768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2009/006146 WO2010007482A2 (en) 2008-07-16 2009-07-03 Thiazole derivatives as stearoyl coa desaturase inhibitors

Country Status (1)

Country Link
WO (1) WO2010007482A2 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110184027A1 (en) * 2008-09-25 2011-07-28 Glenmark Pharmaceuticals S.A. Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification
CN102573493A (en) * 2009-10-20 2012-07-11 H.隆德贝克有限公司 2-substituted-ethynylthiazole derivatives and uses of same
CN102977049A (en) * 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 Method for synthesizing 2-amino-4-cyclopropyl-5-carboxylate thiazole
CN103664819A (en) * 2013-12-16 2014-03-26 山东汇海医药化工有限公司 Preparation method of ethyl 2-amino-4-methylthiazole-5-carboxylate
WO2018129403A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060281A2 (en) * 2002-12-20 2004-07-22 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as kcnq modulators
DE10360369A1 (en) * 2003-12-22 2005-07-14 Bayer Cropscience Ag amides
WO2010035052A1 (en) * 2008-09-25 2010-04-01 Glenmark Pharmaceuticals, S.A. Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04128275A (en) * 1990-09-19 1992-04-28 Mitsubishi Kasei Corp N-benzylamides and insecticidal miticide containing the compound as active component

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004060281A2 (en) * 2002-12-20 2004-07-22 Bristol-Myers Squibb Company 2-aryl thiazole derivatives as kcnq modulators
DE10360369A1 (en) * 2003-12-22 2005-07-14 Bayer Cropscience Ag amides
WO2010035052A1 (en) * 2008-09-25 2010-04-01 Glenmark Pharmaceuticals, S.A. Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199225, Derwent Publications Ltd., London, GB; AN 1992-203174, XP003026938 & JP 4 128 275 A (MITSUBISHI KASEI CORP) 28 April 1992 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110184027A1 (en) * 2008-09-25 2011-07-28 Glenmark Pharmaceuticals S.A. Tissue selective stearoyl-coa desaturase 1 inhibitors and cell based screening assay for their identification
US8440837B2 (en) 2009-10-20 2013-05-14 H. Lundbeck A/S 2-substituted-ethynylthiazole derivatives and uses of same
EP2490541A1 (en) * 2009-10-20 2012-08-29 H. Lundbeck A/S 2-substituted-ethynylthiazole derivatives and uses of same
JP2013508386A (en) * 2009-10-20 2013-03-07 ハー・ルンドベック・アクチエゼルスカベット 2-Substituted-ethynylthiazole derivatives and uses thereof
EP2490541A4 (en) * 2009-10-20 2013-04-10 Lundbeck & Co As H 2-substituted-ethynylthiazole derivatives and uses of same
CN102573493A (en) * 2009-10-20 2012-07-11 H.隆德贝克有限公司 2-substituted-ethynylthiazole derivatives and uses of same
CN102977049A (en) * 2012-11-26 2013-03-20 盛世泰科生物医药技术(苏州)有限公司 Method for synthesizing 2-amino-4-cyclopropyl-5-carboxylate thiazole
CN103664819A (en) * 2013-12-16 2014-03-26 山东汇海医药化工有限公司 Preparation method of ethyl 2-amino-4-methylthiazole-5-carboxylate
US11970486B2 (en) 2016-10-24 2024-04-30 Janssen Pharmaceutica Nv Compounds and uses thereof
WO2018129403A1 (en) 2017-01-06 2018-07-12 Yumanity Therapeutics Methods for the treatment of neurological disorders
US10973810B2 (en) 2017-01-06 2021-04-13 Yumanity Therapeutics, Inc. Methods for the treatment of neurological disorders
US11873298B2 (en) 2017-10-24 2024-01-16 Janssen Pharmaceutica Nv Compounds and uses thereof
US12098146B2 (en) 2019-01-24 2024-09-24 Janssen Pharmaceutica Nv Compounds and uses thereof

Also Published As

Publication number Publication date
WO2010007482A3 (en) 2010-12-02

Similar Documents

Publication Publication Date Title
WO2010007482A2 (en) Thiazole derivatives as stearoyl coa desaturase inhibitors
US10550071B2 (en) PPAR agonists
EP2094662B1 (en) Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents
EP2481725B1 (en) Substituted amide compound
US20080182851A1 (en) Acetylene derivatives as stearoyl coa desaturase inhibitors
JP4974463B2 (en) Indanacetic acid derivatives and their use as pharmaceutical agents, intermediates and methods of preparation
CN102131778A (en) Heterocyclic gpcr agonists
EP3109240A1 (en) Triazine compound and use thereof for medical purposes
JP5369093B2 (en) Pyrimidine derivatives having cytoprotective action and uses thereof
JP2010520162A (en) Thiadiazole derivatives that are stearoyl-CoA desaturase inhibitors
WO2008029266A1 (en) Stearoyl coa desaturase inhibitors
JPWO2006126514A1 (en) Aryl acetic acid derivatives having isoxazole skeleton
WO2021028810A1 (en) Sulfinic acid compounds as free fatty acid receptor agonists
US11905230B2 (en) Phenoxyacetic acid derivatives, preparation method thereof and use thereof as medicament
CN104125960A (en) Derivatives of aza adamantane and uses thereof
JPWO2008108486A1 (en) 1-biarylazetidinone derivatives
KR20120080226A (en) Pyrazole derivatives which modulate stearoyl-coa desaturase
WO2020248327A1 (en) Fatty acid synthase inhibitor and use thereof
WO2006080406A1 (en) Tricyclic compounds
WO2005068467A1 (en) Novel fused-ring compound
CN110372638B (en) Piperazine AMPK agonist and medical application thereof
KR100820935B1 (en) Thiazole derivatives, preparation thereof and pharmaceutical compositions comprising the same
EP2324015A2 (en) Thiophene-2-carboxamide derivatives, preparation thereof and therapeutic use thereof
JP6098001B2 (en) Novel piperidine derivatives, pharmaceutical compositions and uses thereof
CN110372574A (en) Piperidines AMPK agonist and its medical usage

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09797586

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09797586

Country of ref document: EP

Kind code of ref document: A2